

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:
NICKOLSON, Victor

Serial No.: 10/089,542

Group: 1614

Filed: March 29, 2002

Examiner: B. Y. S. Kwon

RECEIVED

APR 20 2004

OFFICE OF PETITIONS

DRUG COMBINATION FOR THE TREATMENT OF HEADACHE
COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG

PETITION UNDER 37 C.F.R. §1.181:
PETITION TO WITHDRAW IMPROPER ABANDONMENT

Honorable Commissioner of Patents
Alexandria, VA 22313

April 12, 2004

Dear Sir:

In response to the Notice of Abandonment and Interview Summary mailed April 7, 2004, Applicants respectfully petition that the Notice of Abandonment is improper and should be withdrawn. Applicants respectfully request withdrawal of the Notice of Abandonment and entry of the Response of September 16, 2003 and Information Disclosure Statement of September 16, 2003.

Response to June 18, 2003 Office Action

Applicants responded timely to the Office Action mailed June 16, 2003. Applicants mailed an Amendment under 37 C.F.R. §1.111 and an Information Disclosure Statement on September 16, 2003. Applicants have attached these documents to this communication.

In addition, Applicants have attached the Certificate of Mailing

RECEIVED
APR 22 2004
TECH CENTER 1600/2900



Under 37 C.F.R. §1.8 signed by Katrina Mears, Intervet Patent Department Administrator.

Applicants respectfully submit that a Response was filed timely.

Interview Summary Analysis

Applicants respectfully address the contents of the Interview Summary. On March 10, 2004, Examiner Kwon contacted Applicants' representative and inquired about a response to the June 18, 2003 Office Action. Applicants can document the date of March 10, 2004 because Applicants' representative responded to the inquiry by resending the Applicants' response to the June 18, 2004 Office Action.

Attached to this communication is the Response to Examiner Telephone Communication that was sent March 10, 2004 to the USPTO by facsimile. Applicants include the facsimile history report that shows that at 5:09 pm March 10, 2004 a facsimile was sent.

Therefore, the Interview Summary is incorrect that March 14, 2004 was a date of communication. Applicants would also note that on April 1, 2004, the second day of communication, Applicants' representative was attending the ABA-IPL CLE course in Washington D.C. and did not receive the voice mail message until his return to the Office in Millsboro, DE on April 5, 2004.

Applicants' representative contacted Examiner Kwon early April

5, 2004 to report that a second response was filed March 10, 2004, but the Examiner reported that the instant Notice of Abandonment had already been mailed.

Therefore, Applicants did respond to both inquiries by the Examiner. Applicants believe they have been diligent in pursuing this application and that the Notice of Abandonment does not reflect any inaction taken by Applicants.

Applicants respectfully request that the abandonment be withdrawn and the Information Disclosure Statement and Response filed September 16, 2003 be considered, because, in fact, they were timely filed.

Patent Term Extension

Applicants respectfully request that any lost patent term due to this improper abandonment be added at the issuance of the patent grant. Applicants believe the time lost should be calculated from the September 16, 2003 day of our timely response to the time this petition is granted and the application is examined by the Examiner.

Conclusion

Applicants filed the response timely and respectfully request the Examiner to consider the attached 37 C.F.R. §1.111 Amendment

and Information Disclosure Statement.


If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (302) 934-4395, in Millsboro, Delaware.

Applicants believe the instant improper abandonment is no fault of applicants; thus no fee should be charged to revive. However, to avoid this petition being dismissed, please charge the petition fee of \$130 as required by 37 C.F.R. §1.17(h) to Deposit Account No. 02-2334.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional

Attorney Docket NO. O/2000.551 US
fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17;
particularly extension of time fees.


Respectfully submitted,



Mark W. Milstead
Associate Patent Counsel
Registration No. 45,825

Akzo Nobel Patent Department
Intervet Inc.
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

Enclosure: 37 C.F.R. §1.111 Amendment 9/16/2003
Information Disclosure Statement 9/16/2003
Response to Examiner Communication 3/10/2004
Copy of Notice of Abandonment



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/92 (08-03)
Approved for use through 07/31/2006. OMB 0561-0031
Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Certificate of Mailing under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on 4/12/04
Date

Katrina M Meas
Signature

Katrina M Meas
Typed or printed name of person signing Certificate

USPN: 10/089542
2000.55105

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Petition (5pgs)

Copy of NOA (14pgs)

Copy of 3/10/04 Resp to Ex Comm (5pgs)

Copy of 37 CFR 1.111 Amended (14pgs)

Copy of cited Ref (3 ref)

Auth to charge fee for Petition

This collection of information is required by 37 CFR 1.8. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.8 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.



Copy of
Notice of Abandonment of
4/7/2004



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/089,542	03/29/2002	Victor Johannes Nickolson	2000.551US	4736
31846	7590	04/07/2004	EXAMINER	
INTERVET INC 405 STATE STREET PO BOX 318 MILLSBORO, DE 19966			KWON, BRIAN YONG S	
			ART UNIT	PAPER NUMBER
			1614	
DATE MAILED: 04/07/2004				

Please find below and/or attached an Office communication concerning this application or proceeding.



**Copy of Response to Examiner
Communication of 3/10/2004**

CERTIFICATE OF FACSIMILE TRANSMISSION

I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.

BY:

Mark W. McQuinn

Date:

2/10/2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:
NICKOLSON, Victor

Serial No.: 10/089,542

Group: 1614

Filed: March 29, 2002

Examiner: B. Y. S. Kwon

For:

DRUG COMBINATION FOR THE TREATMENT OF HEADACHE
COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG

RESPONSE TO EXAMINER TELEPHONE COMMUNICATION

Honorable Commissioner of Patents
Alexandria, VA 22313

March 10, 2004

Sir:

In response to the telephone conversation of March 10, 2004, Applicants respectfully submit the following documents in connection with the above-identified application.

Response to June 18, 2003 Office Action

Applicants responded timely to the Office Action mailed June 16, 2003. Applicants mailed an Amendment under 37 C.F.R. §1.111 and an Information Disclosure Statement on September 16, 2003. Applicants have attached these documents to this communication.

In addition, Applicants have attached the Certificate of Mailing Under 37 C.F.R. §1.8 signed by Katrina Mears, Intervet Patent Department Administrator.

Applicants respectfully submit that a Response was filed timely.

Conclusion


Applicants filed the response timely and respectfully request the Examiner to consider the attached 37 C.F.R. §1.111 Amendment and Information Disclosure Statement.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (302) 934-4395, in Millsboro, Delaware.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional

Attorney Docket NO. O/2000.551 US
fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17;
particularly extension of time fees.

Respectfully submitted,



Mark W. Milstead
Associate Patent Counsel
Registration No. 45,825

Intervet Inc.
Patent Department
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

Enclosure: 37 C.F.R. §1.111 Amendment
Information Disclosure Statement

Mark W. Milstead
40 Indian River Drive
Dagsboro, DE 19939
Phone: 1 302 934 4395
Fax: 302 934 4305

Intervet Inc.

Fax

To: United States Patent and Trademark Office
From: Mark W. Milstead

Fax: 703 872-9306
Date: March 10, 2004

Phone:
Pages: 48

Re: 10/089,542
CC:

☒ **Urgent** ☐ **For Review** ☐ **Please Comment** ☐ **Please Reply** ☐ **Please Recycle**

•Comments:

Re: Nickolson, Victor

10/089,542

Attorney Docket O-2000.551 US

HP OfficeJet T Series
Personal Printer/Fax/Copier/Scanner

Fax History Report for
Intervet Inc.
934 4305
Mar 10 2004 5:27pm

Last Fax

<u>Date</u>	<u>Time</u>	<u>Type</u>	<u>Identification</u>	<u>Duration</u>	<u>Pages</u>	<u>Result</u>
Mar 10	5:09pm	Sent	917038729306	17:11	43	OK

Result:

OK - black and white fax
OK color - color fax

Copy of
37 C.F.R. § 1.111 Amendment of
9/16/2003


Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

**Commissioner for Patents
Alexandria, VA 22313**

On: September 16, 2003

Signature



Typed or Printed Name KATRINA MEARS

**USSN 10/089542
Docket Number O 2000.551**

**Postcard
Amendment (11 pages)
IDS (2 pages)
PTO 1449 (1 page)
Cited References (3)
Fee \$180.00**

September 16, 2003

RE: USSN 10/089542; Docket Number O 2000.551 US

Receipt is acknowledged of the papers and fees listed below in the above identified application:

Mailing Certificate (1 page)
Amendment (11 pages)
IDS (2 pages)
PTO 1449 (1 page)
Cited References (3 ref)
Fee \$180.00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:
NICKOLSON, Victor

Serial No.: 10/089,542 Group: 1614
Filed: March 29, 2002 Examiner: B. Y. S. Kwon
For: DRUG COMBINATION FOR THE TREATMENT OF HEADACHE
COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY DRUG

AMENDMENT UNDER 37 C.F.R. §1.111

Honorable Commissioner of Patents
Alexandria, VA 22313

September 16, 2003

Sir:

In response to the outstanding Office Action mailed June 18, 2003, Applicants respectfully submit the following amendments and remarks in connection with the above-identified application.

In the Claims

1. (Previously Amended) A pharmaceutical composition, comprising:

paracetamol or a non-steroidal anti-inflammatory drug, or a pharmaceutically acceptable salt or solvate thereof,

mirtazapine, or a pharmaceutically acceptable salt or solvate thereof, and

optionally in association with one or more pharmaceutically acceptable carriers.

2. (Previously Amended) The pharmaceutical composition according to claim 1, wherein said non-steroidal anti-inflammatory drug is selected from the group consisting of aceclofenac, antipyrine, acetylsalicylic acid, benoxaprofen, butibufen, caprofen, celecoxib, diclofenac, dipyron, etodolac, flosulide, flurbiprofen, FR 140423, ibufenac, ibuprofen, indomethacin, ketoprofen, ketorolac, lornoxicam, loxoprofen, lysine clonixinate, M-5011, meclofenamic acid, meloxicam, metiazinic acid, nabumetone, naproxen, NS-398, numesulide, oxyphenbutazone, D-penicillamine, phenylbutazone, piroxicam, pyrazolone, rofecoxib, salsalate, salicylate, SC-58236, SC58560, sulfasalazine, sulindac, tiaprofenic acid, tenidap, tenoxicam, tepoxalin, tolfenamic acid, tolmetin and zaltoprofen.

3. (Currently Amended) The pharmaceutical composition

according to claim 2, wherein said non-steroidal anti-inflammatory drug is ~~ibuprofen~~ ibuprofen.

4-8. (Canceled)

9. (Previously Amended) A method for treating a headache in a subject, comprising:

administering to said subject an effective amount of mirtazapine in combination with paracetamol or a non-steroidal anti-inflammatory drug.

10. (Previously Amended) A method of treating a headache in a subject according to claim 9, wherein the amount of mirtazapine is between 0.1 and 5 mg.

11. (Previously Amended) The method of treating a headache in a subject according to claim 9, wherein the headache is a tension-type headache.

12. (Previously Amended) A patient pack for the treatment of a headache, comprising:

means for administration of metered dose units in combination with packaging material suitable for said dose units, wherein the patient pack comprises mirtazapine, and paracetamol or a non-steroidal anti-inflammatory drug, and optionally, said

packaging material is including means to help a recipient using the dose units most suitably for the treatment of a headache.

13. (Previously Amended) The patient pack according to claim 12, wherein the dose units comprise pharmaceutical auxiliaries and mirtazapine in an amount between 0.1 and 5 mg.

14. (Previously Added) A method of treating a headache in a patient, comprising:

administering an effective amount of the pharmaceutical composition according to claim 1.

15. (Previously Added) The method according to claim 14, wherein the effective amount of the pharmaceutical composition comprises about 0.1 to 5 mg of mirtazapine.

16. (Previously Added) The method according to claim 14, wherein the headache is a tension-type headache.

17. (Previously Added) The method according to claim 14, wherein the effective amount of the pharmaceutical composition comprises about 0.1 to 5 mg of mirtazapine and wherein the non-steroidal anti-inflammatory drug is ibuprofen.

18. (NEW) The pharmaceutical composition of claim 1, wherein

mirtazapine is chiral S(+) enantiomer.

19. (NEW) The method of claim 9, wherein mirtazapine is chiral S(+) enantiomer.

REMARKS

Upon entry of the above amendment, claims 1-3 and 9-19 will be pending. Claims 1, 9, and 12 are independent claims.

Applicant has amended claim 3 to correct a typographical error. The specification on page 3 provides support for new claims 18 and 19. Applicant has not raised any issue of new matter.

Priority

The Examiner asserts that Applicant has not filed a certified copy of the EP 00201239.1 application as required by 35 U.S.C. §119(b). Applicant has filed the proper documents with WIPO. Applicant has attached a copy of Form PCT/IB/304 that indicates that Applicant has filed the priority document on July 9, 2001.

Applicant respectfully requests the Examiner to WIPO to send a copy of the priority document.

Issue Under 35 U.S.C. §103(a)

Claims 1-3 and 9-17 stand rejected under 35 U.S.C. §103(a) as being unpatentable over Lange et al (Drugs under Experimental and Clinical Research, 1995, 21(3), 89-96) in view of Olsen '674

(WO 9819674). Applicant asserts that patentable distinctions exist between the cited prior art and the present invention.

Distinctions Between the Present Invention and Lange et al in view of Olsen '674

Lange et al discloses the safety and efficacy of treatment of tension-type headache with either ketoprofen or ibuprofen. Lange et al. fails to disclose a pharmaceutical combination of a NSAID with any other pharmaceutical compound.

Olsen '674 discloses on page 32, lines 7-13 that mirtazapine "may also have an effect on glutamine neurotransmission, potentially as non-competitive NMDA receptor antagonists. It is through this mechanism that [mirtazapine is] presumed to provide a method of treatment of tension-type headaches." The only demonstrated anti-headache effects in Olsen '674 are with L-NMMA (page 74-75), Gabapentin (page 91) and Dextromethorphan (page 93). Olsen '674 provides no mechanistic or structural relation between the exemplified drugs and mirtazapine.

Olsen '674 fails to provide any data to support its assertion; therefore, Olsen '674 is merely speculating as to the action of mirtazapine and many other compounds. For example as to the speculation within Olsen '674, Applicant directs the Examiner to speculative claim 14 where Olsen '674 appears recite every possible mechanistic relationship without any support. More importantly, Olsen '674 fails to disclose any combination

composition for treatment of headaches containing mirtazapine and a NSAID.

The Examiner asserts that a skilled artisan would combine the two cited references to render the present invention obvious because both compounds are "known" treatments of tension-type headaches. As indicated above, Olsen '674 only speculates that mirtazapine might provide a treatment, but provides no actual support for its assertion. Neither reference discloses or suggests combination treatments with mirtazapine. In addition, neither reference suggest the dosage range of 0.1 to 5mg as claimed in claims 10, 13, 15 and 17.

The Examiner must present a *prima facie* case of obviousness consisting of motivation or suggestion to modify or combine references such that one of ordinary skill in the art has a reasonable expectation of success of making the present invention. "To prevent the use of hindsight based on the invention to defeat patentability of the invention, this court requires the examiner to show a motivation to combine the references that create the case of obviousness. In other words, the examiner must show reasons that the skilled artisan, confronted with the same problems as the inventor and with no knowledge of the claimed invention, would select the elements from the cited prior art references for combination in the manner claimed. In re Rouffet, 149 F.3d 1350, 1357, 47 U.S.P.Q.2d 1453, 1457-58 (Fed. Cir. 1998).

Clearly, cited prior art fails to motivate a skilled artisan to make the present pharmaceutical combination of mirtazapine and a NSAID.

Applicant respectfully requests withdrawal of the 35 U.S.C. §103(a) rejection.

Concurrently Filed Information Disclosure Statement

Applicant has filed an IDS concurrently with this amendment and remarks. Applicant believes that these references are not relevant as to the patentability of the present application. Two of the references are self-explanatory. The Demling reference is in German and discusses mianserin and its efficacy against tension headaches. See page 72, left column "war Mianserin gegen Spannungskopfschmerzen." Mirtazapine is discussed as a related compound, but it is stated that there is considerable distinction in pharmacological properties. See page 72, middle column "ein erheblicher Unterschied zwischen beiden Verbindungen in der Verteilung der Elektronendichte und damit auch in den pharmakologischen Eigenschaften." Applicants can prepare an English translation, if the Examiner deems it necessary.

Conclusion


All the stated grounds of the rejections have been properly traversed, accommodated or rendered moot. Applicant respectfully submits that the present application is in condition for

allowance.

If the Examiner believes for any reason that personal communication will expedite prosecution of this application, the Examiner is invited to telephone the undersigned at (302) 934-4395, in Millsboro, Delaware.

If necessary, the Commissioner is hereby authorized in this, concurrent, and further replies, to charge payment or credit any overpayment to Deposit Account No. 02-2334 for any additional fees required under 37 C.F.R. §1.16 or under 37 C.F.R. §1.17; particularly extension of time fees.

Respectfully submitted,

A handwritten signature in dark ink, appearing to read "Mark W. Milstead", is written over a horizontal line.

Mark W. Milstead
Associate Patent Counsel
Registration No. 45,825

Attorney Docket NO. O/2000.551 US

Intervet Inc.
Patent Department
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

MWM

Enclosure: Form PCT/IB/304

PCT/EP01/04069

PATENT COOPERATION TREATY

PCT


NOTIFICATION CONCERNING
SUBMISSION OR TRANSMITTAL
OF PRIORITY DOCUMENT

(PCT Administrative Instructions, Section 411)

From the INTERNATIONAL BUREAU

To:

12 OKT. 2001

KRAAK, H.
P.O. Box 20
NL-5340 BH Oss
PAYS-BAS

Date of mailing (day/month/year)	25 September 2001 (25.09.01)
Applicant's or agent's file reference	2000.551 WO
International application No.	PCT/EP01/04069
International filing date (day/month/year)	04 April 2001 (04.04.01)
International publication date (day/month/year)	Not yet published
Priority date (day/month/year)	05 April 2000 (05.04.00)
Applicant AKZO NOBEL N.V. et al	

IMPORTANT NOTIFICATION

1. The applicant is hereby notified of the date of receipt (except where the letters "NR" appear in the right-hand column) by the International Bureau of the priority document(s) relating to the earlier application(s) indicated below. Unless otherwise indicated by an asterisk appearing next to a date of receipt or by the letters "NR" in the right-hand column, the priority document concerned was submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b).
2. This updates and replaces any previously issued notification concerning submission or transmittal of priority documents.
3. An asterisk(*) appearing next to a date of receipt, in the right-hand column, denotes a priority document submitted or transmitted to the International Bureau but not in compliance with Rule 17.1(a) or (b). In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.
4. The letters "NR" appearing in the right-hand column denote a priority document which was not received by the International Bureau or which the applicant did not request the receiving Office to prepare and transmit to the International Bureau, as provided by Rule 17.1(a) or (b), respectively. In such a case, the attention of the applicant is directed to Rule 17.1(c) which provides that no designated Office may disregard the priority claim concerned before giving the applicant an opportunity, upon entry into the national phase, to furnish the priority document within a time limit which is reasonable under the circumstances.

Priority date	Priority application No.	Country or regional Office or PCT receiving Office	Date of receipt of priority document
05 April 2000 (05.04.00)	00201239.1	EP	09 July 2001 (09.07.01)

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland	Authorized officer David MALEK
Facsimile No. (41-22) 740.14.35	Telephone No. (41-22) 338.83.38

Copy of
Information Disclosure Statement
of 9/16/2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

NICKOLSON, Victor

Serial No.: 10/089,542

Group Art Unit: 1614

Filed: March 29, 2002

Examiner: B.Y.S. Kwon

For: DRUG COMBINATION FOR THE TREATMENT OF HEADACHE COMPRISING A
NON-STEROIDAL ANTI-INFLAMMATORY DRUG

Corresponding to: PCT/EP01/04069, filed April 4, 2001

INFORMATION DISCLOSURE STATEMENT AND TRANSMITTAL
OF FEE PURSUANT TO 37 CFR 1.97(c)

Assistant Commissioner of Patents
Washington, D.C. 20231

September 16, 2003

Sir:

The attention of the Patent and Trademark Office is hereby
directed to the documents listed on the attached Form PTO-1449.

One copy of each of these documents is attached.


This Information Disclosure Statement is being submitted
after issuance of a first official action on the merits and
expiration of the three month period following filing of the
above-captioned application, but prior to issuance of either a
final official action or a Notice of Allowance. The \$180.00 fee
set forth in 37 CFR Section 1.17(p) may be charged to Deposit
Account No. 02-2334

The above information is presented so that the Patent and
Trademark Office can determine any materiality thereof to the
claimed invention. It is respectfully requested that the

information be expressly considered during the prosecution of this application.

The Commissioner is hereby authorized to charge any additional fee (or credit any overpayment) associated with this statement to our Deposit Account No. 02-2334.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Mark W. Milstead", written over a horizontal line.

Mark W. Milstead
Attorney for Applicants
Registration No. 45,825

Intervet Inc Patent Department
Akzo Nobel
405 State Street
P.O. Box 318
Millsboro, DE 19966
Tel: (302) 934-4395
Fax: (302) 934-4305

INFORMATION DISCLOSURE CITATION PTO-1449	Attorney Docket No.	Serial No.
	O 2000.551	10/089,542
	Applicant NICKOLSON, Victor	
	Filing Date	Group
	March 29, 2002	1614

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Translation
	AJ				
	AK				
	AL				
	AM				
	AN				
	AO				
	AP				
	AQ				

OTHER DOCUMENTS

	AR	GREENSHAW ET AL: "The Non-Antiemetic Uses of Serotonin 5-HT3 Receptor Antagonists Clinical Pharmacology and Therapeutic Applications"; Drugs, January 1997, (53) 1; pages 20-39
	AS	DEMLING, J: "Tetrazyklische Antidepressiva: Pharmakologisch-klinische Aspekte und Neuentwicklungen"; Nervenheilkunde 1996: 15:92-100
	AT	LIEH ET AL: "Mechanism of Action of the Antidepressant Mirtazapine"; Abstracts of the 10 th World Congress of Psychiatry, Madrid, August 23-28, 1996, S.l., s.n., 1996; 2:302
	AU	
	AV	
Examiner		Date Considered

REVIEW ARTICLE

Drug 1997 Apr; 53 (1): 20-30
0012-0001/97/0001-0020\$10.00/0

© ADIS International Limited. All rights reserved.

The Non-Antiemetic Uses of Serotonin 5-HT₃ Receptor Antagonists

Clinical Pharmacology and Therapeutic Applications

Andrew J. Greenshaw and Peter H. Silverstone

Department of Psychiatry, University of Alberta, Edmonton, Alberta, Canada

Contents

Summary	20
1. Pharmacotherapy of Anxiety Disorders	22
2. Antipsychotic Effects	25
3. Pharmacotherapy of Drug Abuse and Appetite Disorders	27
4. Involvement of 5-HT ₃ Receptors in Antidepressant Drug Action	29
5. Cognition and the 5-HT ₃ Receptor	30
6. Antinociceptive Effects	31
7. Conclusions	32

Summary

The discovery of multiple subtypes of the serotonin 5-HT receptor has generated enormous interest over the past few years. Possibly the most exciting, in terms of psychiatric clinical practice, appeared to be the 5-HT₃ receptor. Early animal studies suggested that the 5-HT₃ receptor antagonists, in addition to their well recognised antiemetic use, might be clinically useful in a number of areas. These included anxiety disorders, psychotic disorders, drug and alcohol abuse disorders, depressive disorders, cognitive disorders, the treatment of pain and the treatment of irritable bowel syndrome. With the exception of antiemetic actions, this review examines these potential therapeutic areas carefully, paying particular attention not only to the animal literature, but to the clinical studies which have resulted from these initial findings. Unfortunately, studies in many of these therapeutic areas have not lived up to their initial promise. Indeed, no clinical studies have yet clearly demonstrated the usefulness of 5-HT₃ receptor antagonists in the treatment of CNS disorders. Nonetheless, in view of the absence of published results from double-blind, placebo-controlled studies in many of these therapeutic areas, further research would be useful in confirming the effectiveness, or otherwise, of this group of compounds.

There have been many proposals for therapeutic applications of drugs that are antagonists at the recently cloned serotonin 5-HT₃ receptor.^[1-6] The range of the postulated therapeutic potential of these compounds is vast, although their demon-

strated clinical efficacy currently remains limited to antiemetic actions.^[7,8] The promise of these drugs lies in the fact that they appear to have few or no adverse effects in the clinic.

Numerous preclinical reports have suggested

that 5-HT₃ receptor antagonists (fig. 1) may be effective for the treatment of a variety of disorders, particularly psychiatric disorders. The diseases that have been targeted for development of these drugs have included: schizophrenia, anxiety disorders, syndromes of memory impairment that accompany dementia, substance abuse, depression, migraine and, last but not least, irritable bowel syndrome.

The purpose of the present report is to summarise the evidence for potential clinical uses of the 5-HT₃ receptor antagonists. The role of these compounds as useful antiemetics is not discussed in any detail here as this action is well established and has been described.

The excitement that arose when the 5-HT₃ receptor was first identified in the mammalian brain^[9] and when the unique pharmacological properties of this receptor were revealed^[10] provided a tremendous initial burst of research activity. The 5-HT₃ receptor is now quite firmly established as a regulator of neural function. This receptor stands apart from other known 5-HT re-

ceptor subtypes as it resembles receptors of the nicotinic acetylcholine receptor family^[10] (table I). The 5-HT₃ receptor gates a membrane ion channel that conducts monovalent cations such as Na⁺ and K⁺ but excludes anions.^[11]

It has been suggested that as many as 3 subtypes of this 5-HT₃ receptor may be expressed.^[12] This has yet to be confirmed, although there are definite structural and functional differences both within and between species.^[13-15] Current evidence indicates that this receptor exhibits the pentameric structure characteristic of ligand-gated ion channels.^[16] In terms of pharmacological investigation, the 5-HT₃ receptor also stands out from other 5-HT receptors in terms of ligand selectivity. Numerous compounds have been identified as highly selective 5-HT₃ receptor antagonists which readily cross the blood-brain barrier. The high selectivity of these compounds, together with their typically high potency and apparent lack of adverse effects, have made these drugs excellent candidates for potential pharmaceutical drug development.




Fig. 1. Structural formulae of selected serotonin 5-HT₃ receptor antagonists.

Table I. Serotonin 5-HT receptor subtypes^[2]

Name	Selective agonists	Selective antagonists	Transduction mechanism	Molecular identification (species (chromosome))
5-HT _{1A}	8-OH-DPAT	WAY-100635	cAMP (-), K ⁺ channel (+)	Human, mouse (13), rat
5-HT _{1B}	CP-93129		cAMP (-)	Mouse, rat
5-HT _{1C}	Sumatriptan		cAMP (-)	Human (1), rat, dog
5-HT _{1D}	Sumatriptan		cAMP (-)	Human (6)
5-HT _{1E}			cAMP (-)	Human, mouse, rat
5-HT _{1F}			cAMP (-)	Human, mouse, rat
5-HT _{2A}	αMeS-HT	Ketanserin	IP3/DG (+)	Human (13), mouse (14), hamster
5-HT _{2B}	αMeS-HT	LY-053857	IP3/DG (+), Cl ⁻ channel (+)	Human, mouse, rat
5-HT _{2C}	αMeS-HT	Mesulergine	IP3/DG (+), Cl ⁻ channel (+)	Human (X), mouse (X), rat
5-HT ₂	2MeS-HT	Tropisetron	Na ⁺ /K ⁺ internal channel (+)	Rat
5-HT ₄	S-MT	GR-113808	cAMP (+)	Not cloned
5-HT _{5A}			Not known	Mouse, rat
5-HT _{5B}			Not known	Mouse, rat
5-HT ₆			cAMP (+)	Rat
5-HT ₇			cAMP (+)	Human, rat

Abbreviations: S-MT = 5-methoxytryptamine; cAMP = cyclic adenosine monophosphate; IP3/DG = inositol triphosphate/diacylglycerol; MeS-HT = methyl-serotonin.

Selective 5-HT₃ receptor agonists (fig. 2), such as *m*-chlorophenylbiguanide,^[17] have been identified, but most of these compounds do not cross the blood-brain barrier, and this has limited studies with these drugs. The recent discovery of a range of novel 1-heteroaryl-4-alkyl-4-amino-piperidines (such as SR 57227A) which readily cross the blood-brain barrier and exhibit high potency and selectivity as agonists at the 5-HT₃ receptor represents a significant advance in this area.^[18] Nevertheless, since the discovery of the putative 5-HT₄ receptor it is evident that some 5-HT₃ receptor antagonists such as tropisetron and renzapride may also have 5-HT₄ receptor-related activity.^[19]

To date, there has been little attempt to provide a realistic critical evaluation of the growing literature on 5-HT₃ receptor pharmacology in the therapeutic context.^[20] It is now clear that there is very little clinical support for many of the proposals generated by early preclinical studies. In addition, the preclinical research concerning these compounds has not yielded a clear view of their actions in many areas of potential application.

1. Pharmacotherapy of Anxiety Disorders

One property of many putative anxiolytic drugs is their ability to reduce behavioural inhibition due to aversive conditioning in some tests. Di Chiara's group^[21] reported the blockade of acquisition of a drug-conditioned place-aversion by 5-HT₃ receptor antagonists. In such experiments, pairing of a drug (naloxone, phencyclidine or picrotoxin) with the preferred compartment of a 2-compartment apparatus may elicit a significant shift in preference (aversion). Both tropisetron and bemisetron blocked the acquisition of place aversions induced by these compounds. In an earlier study,^[22] diazepam and tropisetron were both shown to inhibit expression of a conditioned place-aversion elicited by footshock.

Such results may indicate anxiety-reducing effects of 5-HT₃ receptor antagonism. Nevertheless, aversive responses to electrical stimulation of the dorsal periaqueductal grey region of the midbrain are unaffected by 5-HT₃ receptor antagonism.^[23] Paradoxically, this implies no influence of 5-HT₃

receptor antagonism on central systems mediating aversive responses.

More recently, the effects of 5-HT₂ receptor antagonism on establishment of conditioned taste aversions induced by nicotine have been examined; no attenuation of the nicotine response was observed. In this study, 5-HT₂ antagonism resulted in the reduction of a taste preference, indicating at least some aversive consequences of 5-HT₂ receptor blockade.^[24]

Various studies indicate the potential for anxiety-reducing effects of 5-HT₂ antagonists in animal models.^[25] Such studies have included the black : white 2-compartment test (in which rodents' increased time in the white compartment is taken to indicate an anxiolytic effect); Sandra File's social interaction test (in which increased social interaction between two unfamiliar rodents is taken to indicate an anxiolytic effect); and the marmoset human-


threat test. In the latter test, changes in both the body postures and the retreat to the rear of the cage which are normally induced by the presence of a human are indicative of anxiolytic action. In contrast to reports of positive anxiolytic responses to 5-HT₂ receptor antagonists such as zacopride, ondansetron, granisetron and tropisetron with these procedures, such compounds usually test negatively in conflict or punishment tests such as the Vogel conflict test: suppression of water-licking subsequent to unavoidable shock.^[25]

Griebel^[26] has reviewed the efficacy of serotonin-related drugs in laboratory animal tests for anxiolytic effects quite extensively and has provided a very useful discussion of this area in a more general context: the reader is referred to this source for a discussion of the possible mismatch between the results of laboratory animal tests and of clinical studies.


Although research on anxiolytic actions of these compounds has been extended to localisation of the possible central site of action to the amygdala,^[27] it is evident that some researchers have failed to observe anxiolytic actions of these compounds in the elevated plus-maze test (a plus-shaped maze with 2 open and 2 closed arms somewhat analogous to the black : white 2-compartment test).^[28] Anxiolytic effects of these compounds have been observed neither in the social interaction test with high levels of social interaction in control animals^[29] nor with socially isolated rats placed in a light : dark shuttlebox.^[30]

Andrews and File^[31] have demonstrated that procedural differences may account for some of the discrepancies in preclinical anxiolytic testing with models such as the elevated plus-maze. In this study the handling history of animals 'blocked' the 'anxiolytic' effects of zacopride and shifted the dose-response to the right for baclofen. This result has important implications for the interpretation of 'anxiolytic' drug effects with respect to between-laboratory differences with the plus-maze and possibly other tests.


Gao and Cutler,^[32] using ethological methods with mice and gerbils, have observed effects which



2-Methyl-serotonin



m-Chlorophenylbiguanide



SR 57227A

Fig. 2. Structural formulae of selected serotonin 5-HT₂ receptor agonists.

have been interpreted as consistent with anxiolytic action. Further positive evidence has been published comparing the novel 5-HT₃ antagonist WAY 100289 to ondansetron, zacopride and tropisetron using the light : dark box and an acoustic startle procedure.^[33] In addition, the novel 5-HT₃ receptor antagonist ricasetron (BRL 46470A) was recently shown to be 100 times more potent than ondansetron and was active in the elevated plus-maze and the social interaction test.^[34] This compound is apparently devoid of the bell-shaped dose-response curve that has made choice of test dose so complex an issue for compounds such as ondansetron.^[34]

The difference between the dose-response function for ricasetron and other 5-HT₃ receptor antagonists has been the focus of interest for generating other selective 5-HT₃ receptor antagonists that may be devoid of the bell-shaped dose-response profile of drugs such as ondansetron, bemisetron and granisetron. In an analysis of the receptor binding profile of [³H]ricasetron, Steward et al.^[35] have demonstrated that this ligand appears to label a higher density of specific 5-HT₃ receptor sites than [³H]granisetron (using ondansetron to define 5-HT₃ receptor binding) in various tissue preparations. The inability of [³H]ricasetron to label the 5-HT₃ receptors expressed in human putamen^[35] emphasises the importance of inter-species differences in 5-HT₃ receptor binding.^[15]

Nevins and Anthony^[36] have evaluated the ability of 5-HT₃ receptor antagonists to reduce the fear-potentiated startle response in rats. These authors report that these compounds are only effective in this test when a relatively low shock intensity is used during training. This is consistent with the idea that only relatively low levels of (experimentally defined) fear or anxiety are affected by 5-HT₃ receptor antagonists.^[36] Neither the anxiogenic nor the discriminative stimulus effects of pentetrazol (pentylenetetrazol) are affected by 5-HT₃ receptor blockade with ondansetron, which is the most widely studied 5-HT₃ receptor antagonist in this context.^[28]

Recently, Olivier et al.^[37] have examined the actions of a variety of putative anxiolytic drugs in two

new animal models: stress-induced hyperthermia in mice and ultrasonic pup vocalisations in rats. 5-HT₃ receptor antagonists were inactive in these tests in contrast to other well established anxiolytics.

In a review of work related to aggression, anxiety and vocalisations in laboratory animals, Miczek et al.^[38] have stated that 5-HT₃ receptor antagonists suppress aggressive behaviour with limited specificity. Despite inconsistencies in the findings from anxiolytic testing (also, see Olivier et al.^[39]) there appears to be some agreement for alleviation of apparent anxiogenic effects of benzodiazepine withdrawal by 5-HT₃ receptor antagonists.^[25,28,40] Nevertheless, at least one study indicates that 5-HT₃ receptor antagonists are ineffective in attenuating hyperlocomotor activity following abrupt termination of long term administration of alcohol (ethanol) or diazepam.^[41] In addition, these compounds may be ineffective in attenuating the increased sensitivity to pentetrazol in alcohol-withdrawn rats.^[41]

Although the 5-HT₃ receptor antagonists may alleviate the apparent anxiogenic effects of benzodiazepine withdrawal they may only be only partially effective (ondansetron) or ineffective in alleviating the anorexia or weight loss in this context.^[42] In terms of physiological responses it is interesting to note that stimulation of 5-HT₃ receptors may result in an increase in adrenocortical secretion in male rats, an effect which is associated with animal models of stress or anxiety.^[43] The increase in plasma corticosterone levels in this study were attenuated by 5-HT₃ receptor antagonism with bemisetron^[43] (but contrast this result with the human volunteer study of Silverstone and Cowen^[44]).

At the neuronal level it is of interest that 5-HT₃ receptors have been implicated in regulation of central cholecystokinin (CCK) release.^[45] Endogenous CCK is currently an important focus of interest in relation to anxiety in the aetiology and treatment of panic disorder, as this neuropeptide is an anxiogenic agent.^[46] Stimulation of 5-HT₃ receptors may be associated with release of cortical

and limbic CKK as the 5-HT₃ receptor antagonists ondansetron, bemisetron and tropisetron reduce CKK-like immunoreactivity.^[43]

At the clinical level, few data are available describing anxiolytic actions of 5-HT₃ antagonists. A study^[29] of ondansetron for the treatment of generalised anxiety disorder has yielded some marginal results: Hamilton Anxiety Rating Scale scores indicated that ondansetron was as effective as diazepam but each treatment group was only slightly (57 to 59%) higher in treatment response than placebo (45%). Using the Montgomery-Åsberg Depression Rating Scale the ondansetron response (54 to 59%) was marginally higher than the diazepam response (51%) or placebo. The rather high relative placebo effect in this study is clearly problematic.

The effects of ricasetron on 'panic' induced by the serotonin agonist *m*-chlorophenylpiperazine (*m*-CPP) have been investigated in an attempt to assess the possible efficacy of 5-HT₃ antagonism in panic disorder. Ricasetron did not attenuate any panic symptoms in this study.^[44] Nevertheless, in a randomised double-blind placebo-controlled trial, Lecrubier and colleagues^[47] reported an anxiolytic effect of tropisetron in patients with generalised anxiety disorder. This statistically significant effect was dose-related in male patients and was detected after 7 days of treatment.

Although there are considerable amounts of preclinical data concerning potential anxiolytic effects of 5-HT₃ antagonists, the clinical evidence is, as yet, far from compelling. What is needed is a series of independent placebo-controlled trials in patients with anxiety disorder. Up to the present time, several 5-HT₃ receptor antagonists have been in clinical trials for anxiolytic action.^[48] So far, there have been no signs of strong contenders in this group of drugs for the clinical management of anxiety and related disorders.

2. Antipsychotic Effects

The earliest behavioural studies indicating central actions of 5-HT₃ antagonists used procedures sensitive to actions of established antipsychotic

drugs.^[49,50] Ondansetron injected intraperitoneally or into the nucleus accumbens of the forebrain inhibited hyperlocomotion induced by intra-accumbens injections of dexamphetamine in rats. Under similar conditions the stimulant effects of peripherally administered amphetamine were unaffected. In other experiments, ondansetron injected intraperitoneally 2 or 3 times daily abolished hyperlocomotion induced by withdrawal from long term infusion of dopamine into the nucleus accumbens in rats or marmosets (anterior ventromedial striatum).

Initial studies had revealed 5-HT₃ antagonists to be devoid of classical neuroleptic effects such as catalepsy, antagonism of stereotyped behaviour or inhibition of conditioned avoidance at doses that completely blocked the von Bezold-Jarisch reflex.^[51] The rather selective profile of action against mesolimbic dopamine-related hyperactivity was initially very exciting as it suggested the possibility of developing a novel class of antipsychotics which would be devoid of the motor adverse effect profile of standard compounds.

Subsequent studies using other procedures have yielded interesting results, but there are clear problems of interpretation for these preclinical findings. Ostensibly, 5-HT₃ antagonists have no effect on 'normal' levels of behavioural output (e.g. basal locomotor activity) or changes in behaviour related to activity of the nigrostriatal dopamine system (e.g. stereotypy following peripheral amphetamine or apomorphine), whereas they may selectively inhibit behaviours associated with stimulation of the mesocorticolimbic dopamine system.

This proposal has some support from studies of effects of 5-HT₃ antagonists on the actions of drugs which induce increased dopamine cell-firing in the ventral tegmental area (and consequently increase dopamine release in the nucleus accumbens). An early study demonstrated that hyperactivity following administration of a stable substance P analogue into the ventral tegmental area may be attenuated by 5-HT₃ receptor antagonism.^[6,52,53] The 5-HT₃ receptor agonist 1-phenyl-biguanide has been reported to increase amphetamine-induced

activity in rats, an effect which was partially attenuated by the 5-HT₃ receptor antagonist bemisetron.^[54] However, the effects of this agonist are now known to be partially attributable to direct actions on the dopamine transporter.^[17,55]

The rewarding effects of nicotine and morphine in conditioned place preference conditioning (the inverse of place-aversion conditioning) are apparently abolished by 5-HT₃ receptor antagonists.^[56,57] Microdialysis studies have indicated that these compounds also block the increase in nucleus accumbens dopamine release induced by these rewarding drugs. Indeed, one study reports abolition of grooming induced by nicotine and a concomitant decrease in release of dopamine from this area following administration of a 5-HT₃ receptor antagonist.^[58]

Electrophysiological studies indicate that the decrease in stimulated dopamine release induced by 5-HT₃ receptor antagonists may not be due a decrease in the drug-stimulated firing rates of dopamine-containing cells in the ventral tegmentum.^[59] Studies of effects of 5-HT₃ receptor antagonists on spontaneous firing rates of these ventral tegmental neurons have yielded mixed results,^[60-62] possibly due to the heterogeneity of the actions of these drugs on 5-HT₃ receptors^[13] and/or their interaction with more recently characterised 5-HT receptor subtypes such as the 5-HT₄ receptor.^[19]

The effects of 5-HT₃ receptor antagonists on stimulated dopamine release and related behaviours described above have not been consistently supported by other studies. Arnold et al.^[24] failed to observe any effect of ondansetron or bemisetron on the hyperactivity induced by repeated intermittent administration of nicotine. This hyperactivity effect was attenuated by the nicotine antagonist mecamylamine and by the dopamine D₂ receptor antagonist haloperidol. Pei et al.^[63] and Moser^[64] have reported a similar lack of selective 5-HT₃ receptor antagonist effects in this context (but see Volonté et al.^[65] and Geissler et al.^[66]).

Several other studies investigating effects of 5-HT₃ receptor antagonism on rewarding effects of

electrical brain self-stimulation or rewarding drug effects believed to be mediated by dopamine release in the nucleus accumbens have failed to support the proposed selective actions of these compounds on stimulated dopamine release in this region.^[67-72] In the studies of ventral tegmental self-stimulation, repeated administration (once or twice daily) of ondansetron failed to alter reward thresholds.^[73] Kozhu et al.^[74] have also reported that repeated administration of ondansetron does not result in a reduction of mesolimbic (or nigrostriatal) dopamine activity in terms of metabolism or receptor binding. In addition, 5-HT₃ receptor antagonists do not appear to influence the reward-enhancing effects of nicotine^[70,72] or the CCK analogue ceruletide (caerulein)^[69] on behaviour maintained by rewarding electrical brain stimulation. Cocaine self-administration in laboratory animals and the discriminative stimulus effects of cocaine are also reported to be unaffected by 5-HT₃ receptor antagonism.^[71]

One interesting and potentially important observation is the ability of 5-HT₃ receptor antagonists such as bemisetron and granisetron to inhibit catalepsy induced by haloperidol in rats.^[75] This has been an area of focus for compounds that interact with 5-HT_{1A} receptors,^[76] and further reports in this area will be of interest.

The early preclinical optimism for antipsychotic potential of these compounds has been dampened both by these subsequent preclinical studies and by the paucity of clinical data indicating any antipsychotic effects of 5-HT₃ antagonists. Although there are case reports and open trials of positive effects (e.g. see White et al.^[77]), no double-blind placebo controlled trials have yet emerged with positive responses.^[78] One single-blind trial of zacopride indicates no clinical benefit in the treatment of acute schizophrenia.^[79] Results from double-blind placebo-controlled studies with ondansetron have been negative.^[60]

Many of the data from clinical trials remain unpublished and it is apparent that some pharmaceutical companies have already withdrawn this class of compounds from trials in this area. One intri-




Fig. 3. Despite a postulated role for serotonin 5-HT₃ receptors in the pathophysiology and treatment of schizophrenia, no changes in receptor affinity (K_d) or density (B_{max}) have been observed for human postmortem brain analysis of schizophrenic or parkinsonian patients. A reduction in the density of these receptors has been reported from postmortem analysis of brain tissue from patients with Huntington's disease.^[82,83]

guing report of a short term open trial of ondansetron for treatment of psychosis in Parkinson's disease is positive.^[61] In this study, ondansetron was claimed to be beneficial for the treatment of patients with advanced Parkinson's disease. The drug was well tolerated and, as expected, induced no major adverse effects.

In view of the balance of available evidence it seems unlikely that 5-HT₃ receptor antagonists will prove to be effective antipsychotics in the foreseeable future. On a purely academic note it is of interest that from postmortem analyses, the density of 5-HT₃ receptors in the human amygdala is unaltered in schizophrenic patients (fig. 3).^[82] In contrast to this result, Steward et al.^[83] have reported reduced levels of these 5-HT₃ receptor recognition sites in the putamen in postmortem analysis of brain tissue from patients who had Huntington's disease (fig. 3).

3. Pharmacotherapy of Drug Abuse and Appetite Disorders

Blockade of conditioned place-preferences to morphine, nicotine and 3,4-methylenedioxy-methamphetamine (MDMA; 'Ecstasy') by 5-HT₃ antagonists has been interpreted as evidence for pos-

sible use of these compounds in the treatment of drug abuse.^[56,57,84] It is notable that although 5-HT₃ receptor antagonists are reported to attenuate locomotor activity induced by cocaine in mice,^[85] the rewarding effects of dexamphetamine, nicotine and cocaine are unaffected by these compounds in rats, as are their discriminative stimulus properties.^[71,86-90]

There is some evidence that the neurochemical correlates of continuous cocaine administration in rats involve an alteration of 5-HT₃ receptor-mediated effects.^[91] Nevertheless, these results do not have obvious implications for a role of this receptor in cocaine abuse as the relevant pattern of drug exposure is intermittent.

One pilot study in human volunteers revealed a decrease in subjective responses to amphetamine following ondansetron; this was not mood-related and the authors were unable to exclude a pharmacokinetic interaction to explain the effect.^[92] A preliminary report has also suggested that the subjective effects of cocaine may be attenuated by ondansetron^[93] – this result has not yet been confirmed.

In relation to opiate drugs there is substantial evidence indicating a 5-HT₃ receptor-mediated blockade of rewarding effects of morphine in the conditioned place-preference paradigm^[56,57,94] and with morphine self-administration in rats.^[95] However, with intravenous self-administration of diamorphine (heroin), 5-HT₃ receptor antagonists (ondansetron and dimesetron) are apparently ineffective.^[96] 5-HT₃ receptor antagonists are also ineffective in blocking the discriminative stimulus properties of morphine.^[97]

A recent innovative study by Sell et al.^[98] examined the effects of ondansetron on opiate-craving in addicts stably maintained on a methadone treatment programme. These individuals experienced significant craving, dysphoria and withdrawal-like symptoms when exposed to a video containing drug-related cues. Ondansetron had no effect on these symptoms. In addition, it is apparent that ondansetron may not reduce cigarette smoking in humans.^[99]

There is some evidence indicating a role for 5-HT₃ receptor antagonism in decreasing alcohol intake in animal studies and in humans.^[100,101] In contrast, 5-HT₃ receptor antagonists may have no effect on consumption of water and saline in laboratory animal tests.^[102] In attempting to determine the mechanisms of 5-HT₃ receptor antagonist effects on alcohol consumption in alcohol-preferring rats Jankowska et al.^[103] have reported that serotonin denervation by neurotoxin lesions did not reduce the alcohol intake-reducing effects of tropisetron. These authors have suggested that the 5-HT₃ receptors that may mediate the tropisetron effects are postsynaptic to serotonin neurons. The effects of these compounds on alcohol intake may possibly represent a clinically meaningful phenomenon.

Sellers et al.^[104] examined the effects of ondansetron in the treatment of alcohol-dependent men. In this randomised placebo-controlled study, reductions in drinking were evident but not statistically significant at 7 weeks. When patients drinking >10 drinks per day at baseline were excluded from the analysis significant reductions in drinking were evident, during ondansetron treatment and at follow-up. Lower baseline drinking and a higher level of education were significant predictors of drinking reduction during treatment.

Johnson and Cowen^[105] have reported preliminary findings that indicate a reduction in the pleasurable effects of a small dose of alcohol and a concomitant reduction in the desire to drink following administration of ondansetron. A more detailed study by Doty et al.^[106] did not reveal any effect of ondansetron on subjective responses to alcohol in a similar context. These authors point out that they used a different alcohol dose from that used by Johnson and Cowen,^[105] and conclude that the utility of ondansetron in treating alcohol abuse may be quite limited if it is only efficacious in blocking the actions of a low dose of alcohol. This latter point has implications for the interpretation of the results of Sellers et al.^[104]

In addition, in a recent preclinical study the 5-HT₃ receptor antagonist bemisetron was reported to exacerbate alcohol withdrawal seizures in mice, al-

though tropisetron was without effect.^[107] This result is directly counter to what may be predicted for a compound that may be useful for the alleviation of symptoms of alcohol abuse. There has been a contrasting report,^[108] in which tropisetron reduced alcohol preference and reduced seizures in alcohol-withdrawn rats. In the former study seizures were induced by handling whereas in the latter study they were audiogenic.

These findings indicate a lack of consistency in responses to 5-HT₃ receptor antagonists, a pattern that is evident in other areas of research. A further result that may reduce confidence in this area in terms of prospective pharmacotherapy is the failure of 5-HT₃ receptor antagonists to alter alcohol self-administration with rats responding on an operant (fixed ratio) self-administration schedule.^[109]

The effects of 5-HT₃ receptor antagonists on rewarding actions of drugs are not general. In the context of pharmacotherapy of drug abuse perhaps treatment of the anxiogenic effects of benzodiazepine withdrawal may represent a useful role for 5-HT₃ antagonists.^[25,28,40]

In terms of influences on behaviour of an appetitive nature there has been some analysis of effects of 5-HT₃ receptor antagonists on sexual behaviour and on feeding. Tanco et al.^[110] examined effects of ondansetron, bemisetron and tropisetron on normal and morphine-induced sexual behaviour in female and male rats. There were no effects of these 5-HT₃ receptor antagonists under the conditions tested.

A subsequent study investigated effects of intracerebroventricular administration of 5-HT₃ receptor agonists.^[111] In this study, 2-methyl-serotonin had no effects but 1-phenyl-biguanide facilitated sexual activity in males. The effects of the latter compound were related to its direct influence on carrier-mediated dopamine release rather than 5-HT₃ receptor-mediated actions. Thus, there seems to be no evidence for 5-HT₃ receptor-mediated influences on sexual behaviour.

Shepherd and Rodgers^[112] reported that ondansetron increased time spent feeding in free-feeding

mice. Administration of tropisetron or bemisetron also increased consumption of amino acid-imbalanced diets in rats,^[113] a finding that has been recently confirmed and extended to blockade of aversion to saccharin presented in an imbalanced amino acid diet.^[114,115] In contrast, Fletcher and Davies^[116] reported that tropisetron increased feeding latency and decreased feeding duration in rats exposed to unfamiliar food but subsequent work indicated that ondansetron had no effects on food intake under a wide variety of feeding conditions.^[117] Tropisetron has also been reported to potentiate the anorectic effect of naloxone.^[118] Studies with ondansetron have also revealed a potentiation of the anorectic effects of dexamphetamine^[119] and a reduction of palatable food consumption in nondeprived rats.^[120]

The relevance of these results to appetitive disorders in the clinical context is unknown. The effects of 5-HT₃ receptor antagonists on the gastrointestinal system are well established, particularly in terms of anti-inflammatory responses and gastrointestinal motility, and this has been the major thrust for drug development in this general area.^[121]

4. Involvement of 5-HT₃ Receptors In Antidepressant Drug Action

The established role of serotonin in antidepressant action has led to some interest in this potential aspect of 5-HT₃ receptor involvement. There has been some interest in antidepressant effects of 5-HT₃ antagonists, initially based on claims that several antidepressant drugs exhibited nanomolar affinity for [³H]quipazine-labelled 5-HT₃ binding sites. Subsequent analysis using [³H]zacopride and [³H]tropisetron to label 5-HT₃ binding sites did not confirm these claims.^[122]

It has recently been reported that the antidepressant drugs clomipramine, fluoxetine and paroxetine interact with both central (NG 108-15 cells) and peripheral 5-HT₃ receptors but do not interact with 5-HT₄ receptors.^[123] In addition, in relation to tropisetron, it has been claimed that 5-HT₃ receptors within the prefrontal cortex may play a role

in fluoxetine-induced increases in extracellular dopamine within this area, although this was not the case with desipramine.^[124]

Electroconvulsive shocks do not alter electrophysiological responses to the 5-HT₃ agonist 2-methyl-serotonin.^[125] Fan^[126,127] has reported an increase in the rate of 5-HT₃ receptor-mediated current desensitisation and an inhibition of peak serotonin current following application of the antidepressants phenelzine, fluoxetine and imipramine in rat nodose ganglion. These results implicate this receptor in the acute actions of antidepressants and also have implications for the mechanisms of action of these drugs on nociceptive responses.

Complementary results have been reported for mianserin and its 6-aza-analogue mirtazapine (ORG-3770). Both compounds displace 5-HT₃ receptor-related ligand binding and reduce 5-HT₃ receptor-mediated currents in N1E-115 neuroblastoma cells.^[128]

Recently, modulation of hippocampal noradrenaline release by the 5-HT₃ receptor agonist 2-methyl-serotonin has been demonstrated in limbic areas of the rat brain, a result with obvious implications for antidepressant potential. Lesioning serotonin neurons with 5,7-dihydroxy-tryptamine did not alter this effect, indicating that the effect is not attributable to a presynaptic serotonin terminal population of receptors.^[129]

The novel selective 5-HT₃ receptor agonist SR-57227A tests positively in a variety of laboratory animal screening tests for antidepressant action.^[130] This compound is the first of a new class of 5-HT₃ receptor agonists that readily cross the blood-brain barrier,^[131] a development that greatly opens up the possibility of exploring effects of 5-HT₃ receptor stimulation in behavioural tests. Also of interest in this area are compounds such as lioxetine, which is a selective serotonin uptake inhibitor with antiemetic properties.^[131] Although lioxetine has been withdrawn from development, drugs such as this may prove to be effective antidepressants with a reduced gastrointestinal adverse effect profile, which can be a problem with the

clinical application of this class of antidepressants.^[132-134]

Disruption of sleep and related EEG activity is quite prominent in affective illness. Of the few reports available to date only one indicates any interesting effects of 5-HT₃ antagonists on sleep/wakefulness in rats. In this study, ondansetron increased paradoxical (rapid eye movement; REM) sleep. Bemisetron decreased both paradoxical and slow wave sleep and increased wakefulness, but only at a very high dose (10 mg/kg).^[135] More recently, tropisetron was found to reduce stage 2 sleep in human volunteers during the entire night and to increase REM sleep during the first third of the night.^[136] In this study, total REM remained unaltered.

5. Cognition and the 5-HT₃ Receptor

The ability of 5-HT₃ receptor antagonists to facilitate cholinergic transmission in cortical brain tissue raised the possibility that these compounds might be effective in treating cholinergic dysfunction,^[137,138] with the important implication being the possible treatment of cholinergic dysfunction in aging, Alzheimer's disease and other functionally similar disorders.

The early claim for facilitation of cholinergic transmission in brain following treatment with 5-HT₃ receptor antagonists has not been consistently supported. Johnson et al.^[139] have reported no significant inhibition or increase in K⁺-stimulated acetylcholine release in slices of rat entorhinal cortex following application of a range of 5-HT₃ receptor ligands at a range of concentrations. These authors have suggested that the role of these receptors in modulating release of acetylcholine needs to be re-examined. A study of human cortical cholinergic axon terminals has also demonstrated the 5-HT₃ receptor-mediated inhibition of acetylcholine release.^[140]

A more recent study has reported that stimulation of 5-HT₃ receptors may induce release of acetylcholine in the dorsal hippocampus of the rat.^[141] The latter results are difficult to reconcile with the claims for 5-HT₃ receptor-mediated inhibition

of acetylcholine release in the cortex, although Consolo and colleagues^[141] have suggested that the actions of 5-HT₃ receptor stimulation may well be regionally selective.

In any event, as both the cortex and hippocampus are important structures in memory processing, the possibility that 5-HT₃ receptor antagonists may be cognitive enhancers is a more complex issue than indicated by the original postulate.^[137] Furthermore, it has been suggested that the doses of ondansetron used in published rodent and marmoset studies (10 ng/kg intraperitoneally in rats and mice and 1 and 10 ng/kg subcutaneously in marmosets) are unlikely to be sufficient to increase the release of acetylcholine centrally;^[142] this remains an empirical question. Nevertheless, a facilitatory role for 5-HT₃ receptor antagonism in hippocampus is supported by Passani et al.^[143] These researchers report an attenuation of serotonin-mediated blockade of long term potentiation in the hippocampus following application of the 5-HT₃ receptor antagonist itasetron (DAU-6215). This compound has been reported to reverse scopolamine (hyoscine)-induced deficits in a spatial learning task in rats^[144] and may attenuate scopolamine-induced deficits in passive avoidance learning^[145] and in spatial learning.^[144] Hodges et al.^[146] have recently observed similar effects of the selective 5-HT₃ receptor antagonist WAX-100289 on spatial memory in rats with neurotoxin-induced lesions of the forebrain cholinergic system.

Early results suggested that ondansetron may enhance cognitive performance in rodents and marmosets^[49] and may enhance performance of marmosets on an object reversal discrimination task.^[138] Ondansetron has also been reported to improve the performance of age-impaired and of atropine-treated rats in a spatial learning task.^[147] The effects of scopolamine in a step-through avoidance learning task may also be blocked by tropisetron.^[148] In another study of long term potentiation, Stäubli and Xu^[149] reported that ondansetron increased the magnitude and duration of this phenomenon. These effects were associated with a dose-dependent increase in hippocampal theta ac-

tivity. In the same study ondansetron also facilitated performance in an odour-matching test and a test of spatial learning.

A failure of ondansetron to reverse scopolamine- or age-related EEG changes in rats has been reported.^[150] and Jakala et al.^[151] failed to observe an improvement of working memory in a delayed matching to sample task in rats. The group that first reported cognitive-enhancing effects of 5-HT₃ receptor antagonists has recently pointed out that the preclinical literature is now inconsistent in this context.^[152] Indeed, these authors reported a failure of ondansetron to attenuate a scopolamine-induced deficit in a Stone maze task and have discussed the apparent task- and dose-related variability of cognitive enhancing effects of these compounds. They point to the heterogeneity of neurochemical substrates underlying regulation of memory processes and to the unusual dose-dependence of 5-HT₃ receptor antagonist effects in this context.

Some evidence has been reported for an enhancement of cognitive functions in human volunteers.^[153,154] In a randomised double-blind, double-dummy, 4-way cross-over design healthy male volunteers were tested acutely with the muscarinic antagonist scopolamine and with the 5-HT₃ receptor antagonist alosetron. The verbal memory deficit induced by scopolamine was attenuated by alosetron.^[154] In a study of age-associated memory impairment ondansetron was administered to healthy nondemented people over 50 years of age who experienced deterioration of memory performance. Ondansetron was administered twice daily for 12 weeks according to a randomised, double-blind, placebo-controlled design.^[153,155] After 12 weeks, the ondansetron-treated group were significantly superior than the placebo group on name-face association acquisition and delayed recall. This effect was dose-dependent, evident at the 250 and 1000 µg doses, but the higher dose effects waned by the end of treatment.

These results are somewhat encouraging, but more positive published clinical data are needed. If they are clinically effective compounds in terms

of 'cognitive-enhancement' the observation that 5-HT₃ receptors are unaltered in the postmortem analysis of the brains of patients with Alzheimer's disease^[156] holds some promise for therapeutic intervention. Nevertheless, in this important area few clinical data have been published to date.

6. Antinociceptive Effects

The ability of the 5-HT₃ agonist 2-methyl-serotonin to mimic, and the antagonists tropisetron and bemisetron to inhibit, peripheral serotonin effects on nociception^[157] strongly suggested a role of 5-HT₃ receptors in pain. Nociceptive responses to intravenous serotonin (measured by tail flick and step-down passive avoidance tests) may be mediated by coactivation of 5-HT₂ and 5-HT₃ receptors located on capsaicin-sensitive vagal afferents.^[158] In addition, several 5-HT₃ receptor antagonists have been reported to inhibit chemical-induced writhing, an effect that may be attributable to a local rather than a central action.^[159] There is considerable evidence for a role for serotonin in the mediation of cardiac pain, and it has been suggested that antagonism of both 5-HT₂ and 5-HT₃ receptors may provide a more effective therapy for treatment of angina and possibly other peripheral serotonin-mediated nociceptive responses.^[158]

The presence of a dense band of 5-HT₃ receptors on capsaicin-sensitive primary afferent terminals in the superficial dorsal horn of the spinal cord^[160-163] has led to investigation of a nociceptive role for 5-HT₃ receptors at this level.^[164] Stimulation of 5-HT₃ receptors by 2-methyl-serotonin blocks scratching and biting induced by substance P and *N*-methyl-D-aspartate (NMDA) applied intrathecally to mice. These antinociceptive effects were blocked by the 5-HT₃ antagonists zacopride and tropisetron, and also by γ -aminobutyric acid (GABA) A and B antagonists, leading to the proposal that 5-HT₃ receptor stimulation in the spinal cord results in a release of GABA which may inhibit nociceptive signal transmission at sites postsynaptic to primary afferent terminals.^[164]

It is interesting to note that supersensitivity to 5-HT₃ receptor agonists has not been observed fol-

lowing serotonin denervation by intrathecal application of 5,7-dihydroxy-tryptamine.^[165] This observation is in agreement with the observations that these receptors are preferentially located on the terminals of primary afferent fibres and that they are decreased following unilateral rhizotomy.^[165] It has been suggested that results such as these with 5-HT₃ receptor-related compounds may herald the development of new nonopioid, nonaddictive analgesics.^[164,166]

In addition, 5-HT₃ receptors have now been clearly identified in the gastrointestinal tract in various species,^[167] and it seems likely that these sites play a significant role in the regulation or mediation of reflexes governing intestinal movement.^[168,169] Several researchers have reported the involvement of these receptor sites in the modulation of visceral hypersensitivity and of stress-induced defecation in rats^[170-172]—in contrast with Gué et al.^[173] These studies indicate considerable potential for 5-HT₃ receptor antagonists in the treatment of irritable bowel syndrome in humans.

Clinical studies to date have yielded some positive results in this area. Prior and Read^[174] reported that ondansetron increased thresholds for perception of sensory effects of rectal distension in patients with irritable bowel syndrome, and similar effects have been observed with granisetron. Ondansetron has, however, been reported to have mixed efficacy in irritable bowel syndrome patients in other studies, and in some cases patients reported increased discomfort.^[175-177] In one study, ondansetron did not alter sensitivity to discomfort or measures of colonic function in patients with this disorder.^[178] Banner and Sanger^[179] have pointed out that the 5-HT₃ receptor antagonists exhibit differential efficacy in the preclinical setting in this context and suggest that, although a correlation between their potencies in preclinical and clinical tests is apparent, this potency does not correlate pharmacologically with the ability of these compounds to antagonise the 5-HT₃ receptor defined *in vitro* or *in vivo* in rats.

It is of considerable interest that clinical benefits have been reported with 5-HT₃ receptor antag-

onists against the pain of migraine. Whereas bemisetron, granisetron and zatosetron appear to be effective in treating this disorder,^[179-182] tropisetron may be only partially effective as an analgesic in this context.^[183] In addition, metoclopramide has been broadly used as an analgesic in the clinic,^[184-188] however, this compound is not selective for 5-HT₃ receptors.

7. Conclusions

It is clear that the 5-HT₃ receptor is functionally of interest from electrophysiological, molecular and neuropharmacological reports, and as the pharmacological profile of 5-HT₃ receptors in terms of controlling release of noradrenaline, acetylcholine, CCK and dopamine in brain continues to evolve. However, there have been several problems for a realistic evaluation of the behavioural actions of these compounds. One glaring factor is that few groups have published consistent positive findings in areas other than nociception and emesis research. In particular, the bell-shaped dose-response curves which seem to be characteristic of effects of some 5-HT₃ receptor antagonists such as ondansetron and tropisetron in some tests make the choice of doses a critical factor in these experiments. For anxiolytic and antipsychotic studies in particular, there are inconsistencies in the literature which are difficult to understand. It is very important to examine the discrepancies between the preclinical behavioural studies, and to examine the emerging mismatch between some of the behavioural and neuropharmacological results.

One of the most attractive features of 5-HT₃ antagonists is the apparent general lack of adverse effects, which are characteristic of most psychotherapeutic drugs. If positive results with double-blind, placebo-controlled clinical trials are forthcoming then the stimulus provided by the early studies will be really worthwhile. So far, the complexity of the preclinical literature concerning 5-HT₃ receptor pharmacology has not been translated into convincing clinical effects for any disorders other than those associated with the processing of noxious stimuli.

Although we will have to wait and see about the outcome of clinical trials it is apparent that we may have a long wait in relation to CNS disorders: many data may simply never be published because of their negative or inconclusive nature. Although the 5-HT₃ receptor is alive and well in terms of modern biology,⁽¹¹⁾ it is perhaps a lesson to us all that the tremendous burst of speculative energy based on early preclinical results has been very disappointing in terms of potential therapeutic uses. This in no way detracts from the excellent profile of these drugs for antiemetic and, to some extent, analgesic applications.

The conclusion of the present review is that, while much of the initial preclinical evidence showed spectacular promise for 5-HT₃ receptor antagonists in the treatment of a wide range of disorders, this promise does not seem to have been upheld. This is a position which has not been well received by some researchers in the field and apparently remains contentious. There are possible explanations for the discrepancies which include methodological problems with the initial studies, lack of relevance of some findings with laboratory animals for human conditions, or an inability of the clinical studies to detect subtle effects of 5-HT₃ antagonists. The extent to which studies with non-human species represent 'models' of psychiatric conditions is of pivotal concern in this context. Changes in animal behaviour observed in such studies are interpreted pragmatically and it is clear that such studies do not reach the criteria of an ideal 'model'.

The available data from studies with 5-HT₃ receptor antagonists suggest that results with certain animal models do not correlate well with human clinical responses. This is well illustrated by the odd findings that these compounds test negatively in some well established anxiolytic models (e.g. conflict procedures) but may show some anxiolytic action in the clinic. Similarly, positive results from some laboratory animal tests of antipsychotic drug action contrast markedly against the failure to observe an antipsychotic response in the clinic. This problem is not restricted to 'models' with labora-

tory animals, for example – the somatic features of anxiety induced by administration of the trazodone metabolite *m*-CPP to human volunteers is blocked by many drugs that have no clinical anxiolytic efficacy.

With this in mind the only pragmatic strategy is to examine drug effects across a wide range of tests to assess their therapeutic potential – in all fairness this has been conducted quite thoroughly in the case of the 5-HT₃ receptor antagonists, with little consistent success. The final possibility is that the 5-HT₃ receptor antagonists do indeed have clinical efficacy but that the clinical studies carried out to date have not been well enough designed to detect these. This issue has been discussed informally by researchers but, to our knowledge, has rarely been entertained in print.

It is necessary to be very careful with this approach. Some studies that we have reviewed^(92,105) have demonstrated subtle effects of 5-HT₃ receptor antagonists on human subjective reports. While these phenomena are of interest, they do not address the core symptoms that patients experience, and may not be of any clinical relevance. Indeed, to be fair, we must accept that a number of large pharmaceutical companies have conducted multicentre trials for these compounds for various psychiatric disorders, including schizophrenia. No positive multicentre data have yet been released following these activities, and some companies have apparently dropped these compounds from development for psychotherapeutic potential. Considering the potential benefits to be derived from the development of clinically effective compounds with an apparent lack of undesirable effects, it seems likely that these compounds would be aggressively explored if the clinical profiles were at all positive. Nevertheless, it is unfortunate that negative outcomes of clinical trials are not widely publicised.

The 5-HT₃ receptor is obviously functionally significant in the CNS. It is highly likely that further research into the structure and function of this receptor will yield important new insights into the regulation of mammalian CNS activity which may

have potential for the development of new therapeutic strategies.

Acknowledgements

The financial support of the Medical Research Council of Canada and the Canadian Psychiatric Research Foundation is gratefully acknowledged by the authors.

References

1. Moolenaar A. Central serotonin receptors: principal fundamental and functional aspects. Therapeutic applications. *Rev Neurol Paris* 1994; 150: 3-15.
2. Palfreyman MG, Scheride CJ, Sorenson SM, et al. Electrophysiological, biochemical and behavioral evidence for 5-HT₂ and 5-HT₃ mediated control of dopaminergic function. *Psychopharmacology* 1993; 112: S60-7.
3. Ellison JM, Flanigan TP, Newberry NR, et al. 5-HT receptor sub-types: aspects of their regulation and function. *Neurochem Int* 1994; 25: S37-43.
4. Tyers MB. 5-HT₂ receptors and the therapeutic potential of 5-HT₂ antagonists. *Therapie* 1991; 46: 431-5.
5. Lausery JM, Callebaut J, Boudoux D, et al. Serotonin receptors and therapeutics. *Cell Mol Biol* 1994; 40: 327-36.
6. Hagan RM, Kilpatrick GJ, Tyers MB. Interactions between 5-HT₂ receptors and cerebral dopamine function: implications for the treatment of schizophrenia and psychoactive substance abuse. *Psychopharmacology* 1993; 112: S68-73.
7. Marty M, Pouillart P, Schol S, et al. Comparison of the 5-hydroxytryptamine-3 (serotonin) antagonist ondansetron (GR38032P) with high-dose metoclopramide in the control of cisplatin-induced emesis. *N Engl J Med* 1990; 322: 816-21.
8. Gyermek L. 5-HT₂ receptors: pharmacologic and therapeutic aspects. *J Clin Pharmacol* 1995; 35: 845-55.
9. Kilpatrick GJ, Jones BJ, Tyers MB. Identification and distribution of 5-HT₂ receptors in rat brain using radioligand binding. *Nature* 1987; 330: 746-8.
10. Dorkach V, Surprenant A, North RA. 5-HT₂ receptors are membrane ion channels. *Nature* 1989; 339: 706-8.
11. Jackson MB, Yakel JL. The 5-HT₂ receptor channel. *Annu Rev Physiol* 1995; 57: 447-68.
12. Bonhaus DW, Stefanich E, Lowry DN, et al. Allosteric interactions among agonists and antagonists at 5-hydroxytryptamine receptors. *J Neurochem* 1995; 65: 104-10.
13. Emerit MB, Martres MP, Miquel MC, et al. Differentiation alters the expression of two splice variants of the serotonin 5-HT₂ receptor-A mRNA in NG108-15 cells. *J Neurochem* 1995; 65: 1917-25.
14. Maricq AV, Peterson AS, Brake AJ, et al. Primary structure and functional expression of the 5-HT₂ receptor, a serotonin-gated ion channel. *Science* 1991; 254: 432-7.
15. Miyake A, Mochizuki S, Takemoto Y, et al. Molecular cloning of human 5-hydroxytryptamine-3 receptor: heterogeneity in distribution and function among species. *Mol Pharmacol* 1995; 48: 407-16.
16. Boess FG, Martin JL. Molecular biology of 5-HT receptors. *Neuropharmacology* 1994; 33: 275-317.
17. Kilpatrick GJ, Butler A, Burridge J, et al. 1-(*m*-Chlorophenyl)-biguanide, a potent high affinity 5-HT₂ receptor agonist. *Eur J Pharmacol* 1990; 182: 193-7.
18. Bachy A, Héaulme M, Giudice A, et al. SR 57272A: a potent and selective agonist at central and peripheral 5-HT₂ receptors in vitro and in vivo. *Eur J Pharmacol* 1993; 237: 299-309.
19. Ford APDW, Clarke DE. The 5-HT₂ receptor. *Med Res Rev* 1993; 13: 633-62.
20. Greenshaw AJ. Behavioural pharmacology of 5-HT₂ receptor antagonists: a critical update on therapeutic potential. *Trends Pharmacol Sci* 1993; 14: 265-70.
21. Acquas E, Carboni E, Garau L, et al. Blockade of acquisition of drug-conditioned place aversion by 5-HT₂ antagonists. *Psychopharmacology* 1990; 100: 459-63.
22. Papp M. Similar effects of diazepam and the 5-HT₂ receptor antagonist ICS 205-930 on place aversion conditioning. *Eur J Pharmacol* 1988; 151: 321-4.
23. Jenck F, Brockhaus CL, Van Delft AM. Effects of serotonin receptor antagonists on PAG stimulation induced aversion: different contributions of 5-HT₁, 5-HT₂ and 5-HT₃ receptors. *Psychopharmacology* 1989; 97: 489-95.
24. Arnold B, Allison K, Ivanova S, et al. 5-HT₂ receptor antagonists do not block nicotine induced hyperactivity in rats. *Psychopharmacology* 1995; 119: 213-21.
25. Costall B, Naylor RJ. The psychopharmacology of 5-HT₂ receptors. *Pharmacol Toxicol* 1992; 71: 401-15.
26. Griebel G. 5-Hydroxytryptamine-interacting drugs in animal models of anxiety disorders: more than 30 years of research. *Pharmacol Ther* 1995; 65: 319-95.
27. Higgins GA, Jones BJ, Oakley NR, et al. Evidence that the amygdala is involved in the disinhibitory effects of 5-HT₂ receptor antagonists. *Psychopharmacology* 1991; 104: 545-51.
28. Rezaeiadeh SM, Prather PL, Ennen-Oglesby MW, et al. Evaluation of anxiolytic action of ondansetron in rats during withdrawal from chronic chlordiazepoxide. *Ann NY Acad Sci* 1992; 264: 472-3.
29. File SE, Johnston AL. Lack of effects of 5-HT₂ receptor antagonists in the social interaction and elevated plus-maze tests of anxiety in the rat. *Psychopharmacology* 1989; 99: 248-51.
30. Moriana A. Effects of the 5-HT₂ receptor antagonists, GR38032F and BRL 2492A, on anxiety in socially isolated rats (abstract). *Br J Pharmacol* 1989; 97: 457P.
31. Andrews N, File SE. Handling history of rats modifies behavioural effects of drugs in the elevated plus-maze test of anxiety. *Eur J Pharmacol* 1993; 235: 109-12.
32. Gao B, Cotler MG. Effects of acute administration of the 5-HT₂ receptor antagonist, BRL-46470A, on the behaviour of mice in a 2 compartment light dark box and during social interactions in their home cage and unfamiliar neutral cage. *Neuropharmacology* 1992; 31: 743-8.
33. Bill DJ, Fletcher A, Glenn BD, et al. Behavioural studies on WAY 100289, a novel 5-HT₂ receptor antagonist, in two animal models of anxiety. *Eur J Pharmacol* 1992; 218: 327-33.
34. Blackburn TP, Baxter GS, Kennen GA, et al. BRL 46047A: a highly potent, selective and long-acting 5-HT₂ receptor antagonist with anxiolytic-like properties. *Psychopharmacology* 1993; 110: 257-64.
35. Seward LJ, Ge J, Bentley KR, et al. Evidence that the atypical 5-HT₂ receptor ligand 3H-BRL4670, labels additional 5-HT₂ binding sites compared to 3H-granisetron. *Br J Pharmacol* 1995; 116: 1781-8.
36. Nevins ME, Anthony EW. Antagonists at the serotonin-3 receptor can reduce the fear-potentiated startle response in the rat: evidence for different types of anxiolytic activity? *J Pharmacol Exp Ther* 1994; 268: 248-68.

37. Olivier B, Molenveld E, van Oershot R, et al. New animal models of anxiety. *Eur Neuropsychopharmacol* 1994; 4: 93-102
38. Miczek KA, Woots EM, Vivian JA, et al. Aggression, anxiety and vocalizations in animals: GABA_A and 5-HT anxiolytics. *Psychopharmacology* 1995; 121: 38-56
39. Olivier B, Mos J, van der Heyden JAM, et al. Anxiolytic properties of 5-HT₃ antagonists: a review. *Stress Med* 1992; 8: 117-36
40. Goodie AJ, Leathley MJ. Effects of the 5-HT₃ antagonist GR38032P (ondansetron) on benzodiazepine withdrawal in rats. *Eur J Pharmacol* 1990; 185: 179-86
41. Mehta AK, Ticku MK. Ethanol- and diazepam-withdrawal hyperlocomotion is not due to 5-HT₃ receptor stimulation. *Pharmacol Biochem Behav* 1993; 45: 755-7
42. Goodie AJ, Leathley MJ. Effects of the 5-HT₃ antagonist ondansetron on benzodiazepine-induced operant behavioural dependence in rats. *Psychopharmacology* 1992; 109: 461-5
43. Saphier D, Welch JE. 5-HT₃ receptor activation in the rat increases adrenocortical secretion at the level of the central nervous system. *Neurosci Res Commun* 1994; 14: 167-73
44. Silvenstone PH, Cowen PJ. The 5-HT₃ antagonist BRL 46470 does not attenuate *m*-chlorophenylpiperazine (mCPP)-induced changes in human volunteers. *Biol Psychiatry* 1994; 36: 309-16
45. Paoletti P, Raisers M. Cholecystokinin release mediated by 5-HT₃ receptors in rat cerebral cortex and nucleus accumbens. *Br J Pharmacol* 1991; 103: 1790-4
46. Harro J, Vasar E, Bradwejn J. Cholecystokinin in animal and human research on anxiety. *Trends Pharmacol Sci* 1993; 14: 244-9
47. Leentveler V, Pouch AJ, Azorin A, et al. A randomised double-blind placebo-controlled study of tropisetron in the treatment of outpatients with generalized anxiety disorder. *Psychopharmacology* 1993; 112: 129-33
48. Mosconi M, Chiambers C, Recchia G. New anxiolytics in development. *Int J Clin Pharm Res* 1993; 13: 331-44
49. Costall B, Domoney AM, Naylor RJ, et al. Effects of the 5-HT₃ receptor antagonist GR38032F on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. *Br J Pharmacol* 1987; 92: 881-94
50. Costall B, Domoney AM, Naylor RJ, et al. Antipsychotic potential of GR38032F, a selective antagonist of 5-HT₃ receptors in the central nervous system [abstract]. *Br J Pharmacol* 1987; 90: 89P
51. Palfreyman MG, Sorensen SM, Baros BM, et al. Antipsychotic potential of 5HT₃ antagonists. In: Meltzer HY, editor. *Novel antipsychotic drugs*. New York: Raven, 1992: 211-23
52. Hagen RM, Butler A, Hill JM, et al. Effect of the 5-HT₃ receptor antagonist, GR38032F, on responses to injection of a neuroleptic agonist into the ventral tegmental area of the rat brain. *Eur J Pharmacol* 1987; 138: 303-5
53. Kriem B, Rostain JC, Abraini JM. Involvement of 5-HT₃ receptor in the pressure-induced increase in striatal and accumbens dopamine release and the occurrence of behavioral disorders in free-moving rats. *Neurosci Lett* 1995; 197: 57-60
54. Laver RT, Uneyk NJ, Walker LJ. Effect of serotonergic agonists in the nucleus accumbens on d-amphetamine-stimulated locomotion. *Life Sci* 1992; 50: 813-20
55. Santiago M, Machado A, Cano J. 5-HT₃ receptor agonist induced carrier-mediated release of dopamine in rat striatum in vivo. *Br J Pharmacol* 1995; 116: 1545-50
56. Chaboni E, Acqros E, Leese P, et al. 5-HT₃ receptor antagonists block morphine- and nicotine- but not amphetamine-induced reward. *Psychopharmacology* 1989; 97: 175-8
57. Higgins GA, Joharchi N, Nguyen P, et al. Effect of the 5-HT₃ receptor antagonist, MDL 72222 and ondansetron on morphine place conditioning. *Psychopharmacology* 1992; 106: 315-20
58. Imperato A, Angelucci L. 5-HT₃ receptors control dopamine release in nucleus accumbens of freely moving rats. *Neurosci Lett* 1989; 101: 214-7
59. Gifford AN, Wong KY. The effect of 5-HT₃ receptor antagonists on the morphine-induced excitation of A10 dopamine cells: electrophysiological studies. *Brain Res* 1994; 638: 325-8
60. Ashby Jr CR, Jiang LM, Wong KY. Chronic BRL43694, a selective 5-HT₃ receptor antagonist, fails to alter the number of spontaneously active midbrain dopamine neurons. *Eur J Pharmacol* 1990; 175: 347-50
61. Rasmussen K, Stockton ME, Czachura JF. The 5-HT₃ antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. *Eur J Pharmacol* 1991; 205: 113-6
62. Sorensen SM, Humphreys TM, Palfreyman MG. Effect of acute and chronic MDL 73,147EF, a 5-HT₃ receptor antagonist, on A9 and A10 dopamine neurons. *Eur J Pharmacol* 1989; 163: 115-8
63. Pei Q, Zetterstrom T, Leslie RA, et al. 5-HT₃ antagonists inhibit morphine-induced stimulation of mesolimbic dopamine release and function in the rat. *Eur J Pharmacol* 1993; 230: 63-8
64. Moser PC. The effect of 5-HT₃ receptor antagonists on the discriminative stimulus effects of amphetamine. *Eur J Pharmacol* 1990; 212: 271-4
65. Volonté M, Ceci A, Borsini F. Effect of the 5-hydroxytryptamine₃ receptor antagonist isasetron (DAU 6214) on (+)-N-allylnormetazocine-induced dopamine release in the nucleus accumbens and in the corpus striatum of the rat: an *in vivo* microdialysis study. *J Pharmacol Exp Ther* 1995; 273: 358-67
66. Geisler MA, Torrence JR, Eison AS, et al. Effects of BMY 33462, a selective and potent serotonin type-3 receptor antagonist, on mesolimbic dopamine-mediated behavior. *Drug Dev Res* 1993; 29: 18-24
67. Greenshaw AJ. Differential effects of ondansetron, haloperidol and clozapine on electrical self-stimulation of the ventral tegmental area. *Behav Pharmacol* 1993; 4: 479-85
68. Dunn RW, Carlsson Jr WA, Corbett R. Preclinical anxiolytic versus antipsychotic profiles of the 5-HT₃ antagonists ondansetron, zacopride, 3-propargyl-1H-indole-3-carboxylic acid ester, and (R, S)-5H-tropas-3-yl-3,5-dichlorobenzoate. *Drug Dev Res* 1991; 23: 289-300
69. Herberg LJ, De Belleruche JS, Rose IC, et al. Effect of the 5-HT₃ receptor antagonist ondansetron on hypothalamic self-stimulation in rats and its interaction with the CCK analogue caerulein. *Neurosci Lett* 1992; 140: 16-8
70. Ivanova S, Allison K, Greenshaw AJ. Effects of ondansetron on the rewarding and aversive stimulus properties of nicotine. *Proceedings of the 16th Annual Meeting of the Canadian College of Neuropsychopharmacology*; 1993
71. Lane JD, Pickering CL, Hooper ML, et al. Failure of ondansetron to block the discriminative or reinforcing stimulus properties of cocaine in the rat. *Drug Alcohol Depend* 1992; 30: 151-62
72. Montgomery AHJ, Rose IC, Herberg LJ. The effect of a 5-HT₃ receptor antagonist, ondansetron, on brain stimulation reward, and its interaction with direct and indirect stimulants of

- central dopaminergic transmission. *J Neural Transm* 1993; 91: 1-11
73. Greenshaw AJ. Differential effects of antipsychotics and the 5-HT₂ antagonist ondansetron on electrical self-stimulation of the VTA in rats [abstract]. *Clin Neuropsychopharmacol* 1992; 15 (B): P88
 74. Korte M, Lappalainen J, Hietala J, et al. Effects of chronic administration of ondansetron (GR38032F), a selective 5-HT₂ receptor antagonist, on monoamine metabolism in mesolimbic and nigrostriatal dopaminergic neurons and on striatal D₂-receptor binding. *Psychopharmacology* 1990; 101: 166-71
 75. Silva SR, Passaro-Neto HA, Pires JGP. Effects of 5-HT₂ receptor antagonists on neuroleptic-induced catalepsy in mice. *Neuropharmacology* 1995; 34: 97-9
 76. McMullen BA, Scott SM, Davanzo EA. Reversal of neuroleptic-induced catalepsy by novel atypical anxiolytic drugs. *J Pharm Pharmacol* 1988; 40: 885-7
 77. White A, Corn T, Fozzard C, et al. Ondansetron in treatment of schizophrenia. *Lancet* 1991; 337: 1173
 78. Breier A. Serotonin, schizophrenia and antipsychotic drug action. *Schizophr Res* 1995; 14: 187-202
 79. Newman JW, Faustman WO, Zipursky RB, et al. Zuclopixide in schizophrenia: a single-blind serotonin type 3 antagonist trial. *Arch Gen Psychiatry* 1992; 49: 751-2
 80. McRiter HY. Studies on ondansetron in schizophrenia. *Biol Psychiatry* 1991; 2: 891-3
 81. Zolman J, Griedberg G, Livneh M, et al. Psychosis in advanced Parkinson's disease: treatment with ondansetron, a 5-HT₂ receptor antagonist. *Neurology* 1995; 45: 1305-8
 82. Abi-Dargham A, Laruelle M, Lipska B, et al. Serotonin 5-HT₂ receptors in schizophrenia: a postmortem study of the amygdala. *Brain Res* 1993; 616: 33-7
 83. Steward LJ, Boulton KE, Hopkins PC, et al. Reduced levels of 5-HT₂ receptor recognition sites in the putamen of patients with Huntington's disease. *Eur J Pharmacol* 1993; 242: 137-43
 84. Bibbig ET, Reid LD. MDL 72222, a serotonin 5-HT₂ receptor antagonist, blocks MDMA's ability to establish a conditioned place-preference. *Pharmacol Biochem Behav* 1991; 39: 50A-12
 85. Reid MEA. 5-HT₂ receptor antagonists attenuate cocaine-induced locomotion in mice. *Eur J Pharmacol* 1990; 186: 327-30
 86. Corrigan WA, Coca KM. Nicotine self-administration and locomotor activity are not modified by the 5-HT₂ antagonists ICS 205-930 and MDL 72222. *Pharmacol Biochem Behav* 1994; 49: 67-71
 87. Paris JM, Connelingham KA. Serotonin 5-HT₂ antagonists do not alter the discriminative stimulus properties of cocaine. *Psychopharmacol* 1991; 104: 475-8
 88. Peltier R, Schenk S. GR38032F, a serotonin 5-HT₂ antagonist, fails to alter cocaine self-administration in rats. *Pharmacol Biochem Behav* 1991; 39: 133-6
 89. Lacosta S, Roberts DCS. MDL 72222, ketanserin, and methysergide pretreatments fail to alter breaking points on a progressive ratio schedule reinforced by intravenous cocaine. *Pharmacol Biochem Behav* 1993; 45: 161-5
 90. Deponoire RY, Li DH, Lane JD, et al. Parameters of self-administration of cocaine in rats under a progressive-ratio schedule. *Pharmacol Biochem Behav* 1993; 45: 1-10
 91. King GR, Xue Z, Calvi C, et al. 5-HT₂ agonist-induced dopamine overflow during withdrawal from continuous or intermittent cocaine administration. *Psychopharmacology* 1995; 117: 458-65
 92. Silverstone PH, Oldman B, Johnson B, et al. Ondansetron, a 5-HT₂ receptor antagonist, partially attenuates the effects of amphetamine: a pilot study in volunteers. *Int Clin Psychopharmacol* 1992; 7: 37-43
 93. Jasinski DR, Preston KL, Teser M, et al. Evaluation of the 5-HT₂ antagonist ondansetron (O) for cocaine (C)-like activity and abuse potential [abstract]. *NIDA Res Monogr* 1991; 105: 515
 94. Bisaga A, Sikova J, Kostowski W. The effects of drugs interacting with serotonin 5-HT₂ and 5-HT₁ receptors on place preference conditioning. *Pol J Pharmacol* 1993; 45: 513-9
 95. Hui S-CQ, Sevilla EL, Ogilvie CW. 5-HT₂ antagonists reduce morphine self-administration in rats. *Br J Pharmacol* 1993; 110: 1341-6
 96. Higgins GA, Wong Y, Corrigan WA, et al. Influence of 5-HT₂ receptor antagonists and the indirect 5-HT agonist, dexfenfluramine, on heroin self-administration in rats. *Psychopharmacology* 1994; 114: 611-9
 97. Joharchi N, Sellers EM, Higgins GA. Effect of 5-HT₂ receptor antagonists on the discriminative stimulus properties of morphine in rats. *Psychopharmacology* 1993; 112: 111-5
 98. Sell LA, Cowen PJ, Robson PJ. Ondansetron and opiate craving: a novel pharmacological approach to addiction. *Br J Psychiatry* 1995; 166: 511-4
 99. Zacny JP, Apfelbaum JL, Lichter JL, et al. Effects of 5-hydroxytryptamine antagonist, ondansetron, on cigarette smoking, smoke exposure and mood in humans. *Pharmacol Biochem Behav* 1993; 44: 387-91
 100. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. *Trends Pharmacol Sci* 1992; 13: 69-75
 101. Grant KA. The role of 5-HT₂ receptors in drug dependence. *Drug Alcohol Depend* 1995; 38: 155-71
 102. Cooper SJ, Barber DJ. Effects of d-fenfluramine, MK-212, and ondansetron on saline drinking in two-choice tests in the rehydrating rat. *Pharmacol Biochem Behav* 1993; 45: 593-6
 103. Jaskowska E, Biziński A, Kostowski W. Alcohol drinking in rats treated with 5,7-dihydroxytryptamine: effect of 8-OH-DPAT and tropic acid (ICS 205-930). *Alcohol* 1994; 11: 283-8
 104. Sellers EM, Tonzano T, Romach MK, et al. Clinical efficacy of the 5-HT₂ antagonist ondansetron in alcohol abuse and dependence. *Alcohol Clin Exp Res* 1994; 18: 879-85
 105. Johnson BA, Cowen PJ. Alcohol-induced reinforcement: dopamine and 5-HT₂ receptor interactions in animals and humans. *Drug Dev Res* 1993; 30: 153-69
 106. Dory P, Zacny JP, de Wit H. Effects of ondansetron pretreatment on acute responses to ethanol in social drinkers. *Behav Pharmacol* 1994; 5: 461-9
 107. Grant KA, Helleuo K, Tabakoff B. The 5-HT₂ antagonist MDL-72222 exacerbates ethanol withdrawal seizures in mice. *Alcoholism: Clin Exp Res* 1994; 18: 410-4
 108. Kostowski W, Dyr W, Krzacik P. The abilities of 5-HT₂ receptor antagonists ICS 205-930 to inhibit alcohol preference and withdrawal seizures in rats. *Alcohol* 1993; 10: 369-73
 109. Beardsley PM, Lopez OT, Gullikson G, et al. Serotonin 5-HT₂ antagonists fail to affect ethanol self-administration of rats. *Alcohol* 1994; 11: 389-95
 110. Tanco SA, Watson NV, Gorzalka BB. Lack of effects of 5-HT₂ antagonists on normal and morphine-attenuated sexual behaviours in female and male rats. *Experientia* 1993; 49: 238-41
 111. Tanco SA, Watson NV, Gorzalka BB. Effects of 5-HT₂ agonists on reproductive behaviors in rats. *Psychopharmacology* 1994; 115: 245-8

112. Shepherd JK, Rodgers RL. 8-OH-DPAT specifically enhances feeding behaviour in mice: evidence from behavioural competition. *Psychopharmacology* 1990; 101: 408-13.
113. Hammer VA, Gietzen DW, Beverly JL et al. Serotonin 3 receptor antagonists block anorectic responses to amino acid imbalance. *Am J Physiol* 1990; 259: R627-36.
114. Jiang JC, Gietzen DW. Aromatic response to amino acid imbalance: a selective serotonin-3 effect. *Pharmacol Biochem Behav* 1994; 47: 59-63.
115. Terry-Nathana VR, Gietzen DW, Rogers QR. Serotonin antagonists block aversion to saccharin in an amino acid-imbalanced diet. *Am J Physiol* 1995; 268: R1203-8.
116. Fletcher PJ, Davies M. Effects of 8-OH-DPAT, buspirone and ICS 205-930 on feeding in a novel environment: comparison with chlordiazepoxide and FG-7142. *Psychopharmacology* 1990; 102: 301-8.
117. Higgins GA, Tomkins DM, Fletcher PJ et al. Effect of drugs influencing 5-HT function on ethanol drinking and feeding behavior in rats: studies using a drinkometer system. *Neurosci Biobehav Rev* 1992; 16: 333-32.
118. Boczkowska IW, Bodnar RJ. Naloxone and serotonin receptor subtype antagonists: interactive effects upon deprivation-induced intake. *Pharmacol Biochem Behav* 1991; 38: 605-10.
119. Cooper SJ, Greenwood SE, Gilbert DB. The selective 5-HT₃ receptor antagonist ondansetron augments the anorectic effects of d-amphetamine in non-deprived rats. *Pharmacol Biochem Behav* 1993; 45: 589-92.
120. van der Hock GA, Cooper SJ. Ondansetron, a selective 5-HT₃ antagonist reduces palatable food consumption in the non-deprived rat. *Neuropharmacology* 1994; 33: 805-11.
121. Silverstone PH, Greenhaw AJ. 5-HT₃ receptor antagonists. *Expert Opin Ther Patents* 1996; 6: 471-81.
122. Hoyer D, Waeber C, Karpf A et al. [3H]-ICS 205-930 labels 5-HT₃ recognition sites in membranes of cat and rabbit vagus nerve and superior cervical ganglion. *Naunyn-Schmiedeberg Arch Pharmacol* 1989; 340: 396-402.
123. Lucchelli A, Santagostino-Barbone MG, Barbieri A et al. The interaction of antidepressant drugs with central and peripheral (enteric) 5-HT₂ and 5-HT₃ receptors. *Br J Pharmacol* 1995; 114: 1017-25.
124. Tanda G, Frau R, Di Chiara G. Local 5-HT₃ receptors mediate fluoxetine but not desipramine-induced increase of extracellular dopamine in the prefrontal cortex. *Psychopharmacology* 1993; 119: 15-9.
125. Blier P, Boechard C. Functional characterization of a 5-HT₃ receptor which modulates the release of 5-HT in the guinea pig brain. *Br J Pharmacol* 1993; 108: 13-22.
126. Fan P. Effects of antidepressants on the inward current mediated by 5-HT₃ receptors in rat nodose ganglion neurones. *Br J Pharmacol* 1994; 112: 741-4.
127. Fan P. Inhibition of a 5-HT₃ receptor-mediated current by the selective serotonin uptake inhibitor, fluoxetine. *Neurosci Lett* 1994; 173: 210-2.
128. Kooyman AR, Zwart R, Vanderheijden PML et al. Interaction between enantiomers of mianserin and ORG3770 at 5-HT₃ receptors in cultured mouse neuroblastoma cells. *Neuropharmacology* 1994; 33: 501-7.
129. Mongeau R, De Montigny C, Blier B. Activation of 5-HT₃ receptors enhances the electrically evoked release of [³H]noradrenaline in rat brain limbic structures. *Eur J Pharmacol* 1994; 256: 269-79.
130. Poncelet M, Péro A, Simard J et al. Antidepressant-like effects of SR 57227A, a 5-HT₃ receptor agonist, in rodents. *J Neural Trans* 1995; 102: 83-90.
131. Angel I, Schoemaker H, Protlein M et al. Lixoxetine: a selective 5-HT uptake inhibitor with concomitant 5-HT₃ receptor antagonist and antiemetic properties. *Eur J Pharmacol* 1993; 232: 139-45.
132. Boyer WF, Feighner JP. An overview of fluoxetine, a new serotonin-specific antidepressant. *Moum Sinai J Med* 1989; 56: 136-40.
133. Feighner JP, Boyer WF, Meredith CJ et al. A placebo controlled inpatient comparison of fluvoxamine maleate and imipramine in major depression [abstract]. *Int Clin Psychopharmacol* 1989; 4: 239.
134. Laws D, Ashford JJ, Amster JA. A multicenter double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice [abstract]. *Acta Psychiatr Scand* 1990; 81: 185.
135. Adrien J, Tissier MH, Lanfimey L et al. Central action of 5-HT₃ receptor ligands in the regulation of sleep-wakefulness and rapid neuronal activity in the rat. *Neuropharmacology* 1992; 31: 519-29.
136. Rothe B, Bultmer J, Hoffeldt E et al. Effects of 5-HT₃ receptor antagonism by tropisetron on the sleep EEG and on nocturnal hormone secretion. *Neuropsychopharmacology* 1994; 11: 101-6.
137. Barnes JM, Barnes NM, Costall B et al. 5-HT₃ receptors mediate inhibition of acetylcholine release in cortical tissue. *Nature* 1989; 338: 762-3.
138. Domeney AM, Costall B, Gerrard PA et al. The effect of ondansetron on cognitive performance in the marmoset. *Pharmacol Biochem Behav* 1991; 38: 169-73.
139. Johnson RM, Inouye GT, Eglen RM et al. 5-HT₃ receptor ligands lack modulatory influence on acetylcholine release in rat entorhinal cortex. *Naunyn-Schmiedeberg Arch Pharmacol* 1993; 347: 241-7.
140. Mauro G, Andrioli GC, Cavazzani P et al. 5-Hydroxytryptamine-3 receptors sited on cholinergic axon terminals of human cerebral cortex mediate inhibition of acetylcholine release. *J Neurochem* 1992; 58: 2334-7.
141. Corrado S, Bertorelli R, Ruzi G et al. Serotonergic facilitation of acetylcholine release in vivo from rat dorsal hippocampus via serotonin 5-HT₃ receptors. *J Neurochem* 1994; 62: 2254-61.
142. Dawson GR, Heyes CM, Iversen SD. Pharmacological mechanisms and animal models of cognition. *Behav Pharmacol* 1992; 3: 285-97.
143. Passani MB, Peglase AM, Azzurini M et al. Effects of DAU 6215, a novel 5-hydroxytryptamine-3 (5-HT₃) antagonist on electrophysiological properties of the rat hippocampus. *Br J Pharmacol* 1994; 112: 695-703.
144. Pitsikas N, Brambilla A, Bonini F. Effect of DAU 6215, a novel 5-HT₃ receptor antagonist, on scopolamine-induced amnesia in the rat in a spatial learning task. *Pharmacol Biochem Behav* 1994; 47: 95-9.
145. Brambilla A, Ghiorzi A, Pitsikas N et al. DAU 6215, a novel 5-HT₃ receptor antagonist, selectively antagonizes scopolamine-induced deficit in a passive-avoidance task, but not scopolamine-induced hypermotility in rats. *J Pharm Pharmacol* 1993; 45: 841-3.
146. Hodges H, Sowinski P, Sinden JD et al. The selective 5-HT₃ receptor antagonist, WAY100289, enhances spatial memory

- in rats with ibotenic lesions of the forebrain cholinergic projection system. *Psychopharmacology* 1995; 117: 318-32
147. Fontana DJ, Daniels SE, Henderson C, et al. Ondansetron improves cognitive performance in the Morris water maze spatial navigation task. *Psychopharmacology* 1995; 120: 409-17
 148. Cheng Y, Saha N, Sankaranarayanan A, et al. Enhancement of memory retrieval and attenuation of scopolamine-induced amnesia following administration of 5-HT₂ antagonist ICS 205-930. *Pharmacol Toxicol* 1991; 69: 105-6
 149. Sitabli U, Xu FB. Effects of 5-HT₂ receptor antagonism on hippocampal theta rhythm, memory and LTP induction in the freely moving rat. *J Neurosci* 1995; 15: 2445-52
 150. Reikkinen J, P. Sirviö J, Reikkinen P. Non-reversal of scopolamine- or age-related EEG changes by ondansetron, methylsergide or alaproclate. *Psychopharmacology* 1991; 103: 567-70
 151. Jakala P, Sirviö J, Reikkinen PJ. The effects of tacrine and zacopride on the performance of adult rats in the working memory task. *Gen Pharmacol* 1994; 24: 675-9
 152. Bratt AM, Kelly E, Domesey AM, et al. Ondansetron fails to attenuate a scopolamine-induced deficit in a Stone maze task. *Neuroreport* 1994; 5: 1921-4
 153. Preston GC. 5-HT₂ antagonists and disorders of cognition. In: Racagni G, Bruscolini N, Langer SZ, editors. Recent advances in the treatment of neurodegenerative disorders and cognitive dysfunction. *Int Acad Biomed Drug Res Basel, Karger*. 1994; 7: 89-93
 154. Preston GC, Milnes DS, Coopers PR, et al. Effects of the 5-HT₂ receptor antagonist GR68755 on a scopolamine-induced cognitive deficit in healthy subjects (abstract). *Br J Clin Pharmacol* 1991; 32: 546P
 155. Crook TH, Lakso M. Effects of ondansetron in age-associated memory impairment. *Proceedings of 5th World Congress of Psychiatry*; 1991: Florence
 156. Barnes NM, Costall B, Naylor RJ, et al. Normal densities of 5-HT₂ receptor recognition sites in Alzheimer's disease. *Neuroreport* 1990; 1: 253-4
 157. Glenn SR, Proudfoot HK, Anderson EG. 5-HT₂ receptors modulate spinal nociceptive reflexes. *Brain Res* 1990; 510: 12-6
 158. Meltzer ST, Lewis SJ, Brody MJ, et al. Vagal afferent-mediated inhibition of a nociceptive reflex by iv serotonin in the rat II: role of the 5-HT receptor subtypes. *Brain Res* 1992; 585: 71-86
 159. Moter PC. The effect of 5-HT₂ receptor antagonists on the writhing response in mice. *Gen Pharmacol* 1995; 26: 1301-6
 160. Gehlert DR, Gockeheimer SL, Wong DT et al. Localization of 5-HT₂ receptors in the rat using [³H] LY278584. *Brain Res* 1991; 553: 149-54
 161. Harmon M, Gallissot MC, Meunier F, et al. 5-HT₂ receptor binding sites are on capsaicin-sensitive fibres in rat spinal cord. *Eur J Pharmacol* 1989; 164: 313-22
 162. Kie HK, Miquel M-C, McKernan RM, et al. Localization of 5-HT₂ receptors in the rat spinal cord: immunohistochemistry and *in situ* hybridization. *Neuroreport* 1995; 6: 257-61
 163. Laporte AM, Koscielnik T, Pouchet M, et al. Quantitative autoradiographic mapping of 5-HT₂ receptors in the rat CNS using [¹²⁵I] iodo-zacopride and [³H] zacopride as radioligands. *Synapse* 1992; 10: 271-81
 164. Alhalder AA, Lei SZ, Wilson GL. Spinal 5-HT₂-mediated antinociception - possible release of GABA. *J Neurosci* 1991; 11: 1881-8
 165. Sawynok J, Reid A. Spinal supersensitivity to 5-HT₂, 5-HT₁, and 5-HT₃ receptor agonists following 5,7-dihydroxytryptamine. *Eur J Pharmacol* 1994; 264: 249-57
 166. Alhalder AA, Harmon M, Wilson GL. Intrathecal 5-methoxy-N,N-dimethyltryptamine in mice modulates 5-HT₁ and 5-HT₂ receptors. *Eur J Pharmacol* 1993; 249: 151-60
 167. Champavert S, Costall B, Naylor RJ, et al. Identification and distribution of 5-HT₂ recognition sites in the rat gastrointestinal tract. *Br J Pharmacol* 1992; 106: 693-6
 168. Yuan SY, Bornstein JC, Furness JB. Investigation of the role of 5-HT₂ and 5-HT₁ receptors in ascending and descending reflexes to the circular muscle of guinea-pig small intestine. *Br J Pharmacol* 1994; 112: 1095-100
 169. Sanger GJ, Wardle KA. Constipation evoked by 5-HT₂ receptor antagonism: evidence for heterogeneous efficacy among different antagonists in guinea-pigs. *J Pharm Pharmacol* 1994; 46: 666-70
 170. Bawer SE, Sanger GJ. Differences between 5-HT₂ receptor antagonists in modulation of visceral hypersensitivity. *Br J Pharmacol* 1993; 114: 558-62
 171. Morim O, Julia V, Eeckhout C, et al. Influence of 5-HT₂ receptor antagonists in visceromotor and nociceptive responses to rectal distension before and during experimental colitis in rats. *Fundam Clin Pharmacol* 1994; 8: 553-62
 172. Kishibayashi N, Miwa Y, Hayashi M, et al. 5-HT₂ receptor antagonists: 3. Quinoline derivatives which may be effective in the therapy of irritable bowel syndrome. *J Med Chem* 1993; 36: 3286-92
 173. Gao M, Atary C, Del Rio-Lachez C, et al. Comparative involvement of 5-HT₁, 5-HT₂ and 5-HT₃ receptors in stress-induced colonic motor alterations in rats. *Eur J Pharmacol* 1993; 233: 193-9
 174. Prior A, Read NW. Reduction of rectal sensitivity and postprandial motility by granisetron, a 5-HT₂ receptor antagonist, in patients with irritable bowel syndrome (IBS) (abstract). *Gut* 1990; 31: A1174
 175. Mason DG, Haigh CG, Whorwell PJ. Clinical trial of ondansetron, a selective 5-HT₂ antagonist in irritable bowel syndrome (IBS) (abstract). *Gastroenterol* 1991; 100: A468
 176. Scudama CJ, Talley NJ, Phillips SF, et al. Trial of a selective serotonin (type 3 (5-HT₃)) antagonist ondansetron (GR13032F) in diarrhoea predominant irritable bowel syndrome (IBS) (abstract). *Gastroenterology* 1990; 98: A394
 177. Scudman CJ, Talley NJ, Phillips SF, et al. Selective 5-hydroxytryptamine type 3 receptor antagonism as treatment for diarrhoea-predominant irritable bowel syndrome - a pilot study. *Mayo Clin Proc* 1992; 67: 732-8
 178. Hammer J, Phillips SF, Talley NJ, et al. Effect of a 5-HT₂ antagonist (ondansetron) on rectal sensitivity and compliance in health and irritable bowel syndrome. *Aliment Pharmacol Ther* 1993; 7: 543-51
 179. Loisy C, Baorchia S, Contoux V, et al. Effects on migraine headache of MDL 72222, an antagonist at neuronal 5-HT receptors, double-blind, placebo-controlled study. *Cephalalgia* 1985; 5: 79-82
 180. Cowterley EGM, Hering R, Foster CA, et al. First clinical study of the selective 5-HT₂ antagonist, granisetron (BRL 43694), in the acute treatment of migraine headache. *Headache* 1991; 31: 296-7
 181. Rowat BMT, Merrill CF, Davis A, et al. A double-blind comparison of granisetron and placebo for the treatment of acute

- migraine in the emergency department. *Cephalalgia* 1991; 11: 207-13
182. Chappell AS, Bay JM, Borzum GD, et al. Zanictron, a 5-HT₂ receptor antagonist in a multicenter trial for acute migraine. *Neuropharmacology* 1994; 33: 509-13
 183. Ferrari MD, Wilkinson M, Hirt D, et al. Efficacy of ICS 205-930, a novel 5-hydroxytryptamine-3 5-HT₂ receptor antagonist, in the prevention of migraine attacks: a complex answer to a simple question. *Pain* 1991; 45: 283-92
 184. Hughes JB. Metoclopramide in migraine treatment. *Med J Aust* 1977; 2: 580
 185. Grauers O, Daneskiold-Samsøe P, Hasselgren KH, et al. Metoclopramide in acute pain caused by gallbladder or kidney-stones [abstract]. *Scand J Gastroenterol* 1982; 17: A886
 186. Rosenblatt WF, Cioffi AM, Sizaro R, et al. Metoclopramide: an adjunct to patient-controlled analgesia. *Anesth Analg* 1991; 73: 553-5
 187. Coppola M, Yealy DM, Lichold RA. Randomized placebo-controlled evaluation of prochlorperazine versus metoclopramide for emergency department treatment of migraine headache. *Ann Emerg Med* 1995; 26: 541-6
 188. Kauder D, Lisander B. Analgesic action of metoclopramide in prosthetic hip surgery. *Acta Anaesthesiol Scand* 1993; 37: 49-53

Correspondence and reprints: Dr A.J. Greenshaw, Department of Psychiatry, 1E7.44 W.M.C., University of Alberta, Edmonton, Alberta, T6G 2B7, Canada.
E-mail: andy.greenshaw@ualberta.ca

J. Demling

Psychiatrische Klinik
der Universität Erlangen-Nürnberg
(Direktor: Prof. Dr. E. Lungenhausen)

Tetrazyklische Antidepressiva:

Pharmakologisch-klinische Aspekte und Neuentwicklungen

Das Thema des Erlanger nervenärztlichen Fortbildungskongresses 1995 lautete: »Neue Methoden in der Behandlung mit Psychopharmaka«. Hierunter kann folgendes verstanden werden:

1. Änderungen in der Anwendung eines Psychopharmakons im ursprünglichen Indikationsbereich, also zusätzliche Applikationsformen, Höherdosierung oder die Kombination mit anderen psychotropen Substanzen. Beispiele sind die Einführung parenteral applizierbarer Psychopharmaka und der Depot-Neuroleptika. Von Versuchen einer Hochdosisbehandlung mit Neuroleptika Ende der siebziger Jahre ist man bekanntlich wieder abgekommen, aktuell ist dagegen etwa die Hochdosierung pflanzlicher Psychotropika wie des Antidepressivums Hypericin, aber auch verbesserte Therapieerfolge mit dem tetrazyklischen Antidepressivum Mianserin durch höhere Tagesdosen. Die Kombination eines Antidepressivums etwa mit Lithium bewirkt über eine »Augmentation« eine verbesserte Stimmungsaufhellung.
2. Behandlung von Erkrankungen außerhalb des ursprünglichen psychiatrischen Indikationsbereiches mit Psychopharmaka, etwa die Behandlung von Schmerz- und von Entzugssyndromen, aber auch von gastrointestinalen Ulzera oder von juckenden Dermatosen mit trizyklischen Antidepressiva, z.B. Doxepin oder Amitriptylin. Zwangs- und bulimische Störungen sprechen auf selektive Serotonin-Rückaufnahmehemmer (SSRI: Fluoxetin, Fluvoxamin, Paroxetin, Citalopram) an. Lorazepam erwies sich gegen stuporöse Zustände als gut wirksam. Mianserin läßt sich erfolgreich zur Behandlung chronischer Schmerzzustände und unter weiteren Indikationen einsetzen (siehe unten).

Schlüsselwörter

Mianserin, Mirtazapin, Setiptilin, Org 4428, Piperazino-Azepine, tetrazyklische Antidepressiva

Zusammenfassung

Mianserin steht auf dem bundesdeutschen Arzneimittelmarkt seit nunmehr 20 Jahren als einziges »genuines« tetrazyklisches Antidepressivum einer großen und wechselnden Zahl trizyklischer Substanzen gegenüber. Es gehört unter den »neueren« Antidepressiva zu den am besten dokumentierten Substanzen und zeichnet sich, auch in höherer Dosierung, durch sehr gute Verträglichkeit aus. Neben stimmungsaufhellenden, anxiolytischen und schlafanstoßenden Eigenschaften konnte in einer Reihe von Studien die Wirksamkeit von Mianserin gegen weitere Beschwerdebilder, insbesondere Schmerzzustände unterschiedlicher Genese, gezeigt werden. Für 1996 wird die Markteinführung von Mirtazapin in der Bundesrepublik erwartet, eines Antidepressivums, das strukturell wie Mianserin aus einem Ringsystem vom tetrazyklischen Piperazino-Azepintyp besteht, aber ein etwas anderes pharmakologisches Wirkspektrum aufweist. Die antidepressiven Eigenschaften von Mirtazapin sind mittlerweile gut belegt. Wie diese und weitere Entwicklungen (Setiptilin, Org 4428) zeigen, wohnt dem tetrazyklischen Grundgerüst nach Art des Mianserin ein antidepressives Wirkpotential inne, das noch nicht ausgeschöpft ist und neue Möglichkeiten der pharmakopsychiatrischen Therapie eröffnet.

Keywords

Mianserin, mirtazapine, setiptiline, Org 4428, piperazino-azepines, tetracyclic antidepressants

Summary

Mianserin has been on the German market for over 20 years and is the only genuine tetracyclic antidepressant available in the large and changing field of tricyclic substances. Being one of the »newer« antidepressants, it is also one of the best documented compounds, and it has a safe profile of unwanted side effects, even when given in higher dosages. Apart from its effects on mood improvement, reduction of anxiety and sleep enhancement, a number of studies have demonstrated its efficacy against other syndromes, especially pain syndromes of different origin. The introduction of the antidepressant mirtazapine into the German market is expected in 1996. Like mianserin, mirtazapine consists of a tetracyclic structure of the piperazino-azepine type but has a somewhat different pharmacological profile. The antidepressant properties of mirtazapine have been positively acknowledged and demonstrated. In addition, further developments such as setiptiline and Org 4428 show that the beneficial effects of this tetracyclic structure have not yet been exhausted and new possibilities remain to be discovered.

3. Behandlungsversuche psychischer Störungen mit Pharmaka aus anderen psychiatrischen oder aus nicht-psychiatrischen Indikationsbereichen. Dabei wurde eine spezielle

psychotrope Wirkung entweder zufällig entdeckt (im tierexperimentellen Screening oder bei der klinischen Anwendung) oder aufgrund theoretischer Überlegungen postuliert.

Durch strukturelle Veränderungen ließ sich oftmals die Eignung einer Substanz für das neue Indikationsgebiet verbessern. Beispiele sind zahlreiche, etwa die ersten MAO-Inhibitoren, die – wie Iproniazid – als Tuberkulostatika eingesetzt waren bzw. aus diesen hervorgingen, oder die trizyklischen Antidepressiva (Imipramin), Abkömmlinge der Neuroleptika, letztlich also der Antihistaminika. Auch das Antidepressivum Mianserin ist ein »Nebenprodukt« der Antihistaminikaforschung. Als neuartige potentielle Antidepressiva befinden sich Kalziumantagonisten, ACE-Hemmer, Kortisol-Syntheseinhibitoren und weitere Pharmakagruppen in der Erprobung bzw. Entwicklung (66).

4. Behandlung psychischer Erkrankungen mit neuen Substanzen, die anders als ältere »dirty drugs« mit ihren vielfältigen Rezeptoraffinitäten, bekannte psychoaktive Wirkprinzipien – etwa auf der Basis der Aminmangelhypothesen – in »reiner« Form verkörpern oder modifiziert aufweisen. Auf dem Antidepressivasektor lassen sich hier die Substanzen der »zweiten Generation« anführen, etwa die SSRI sowie

Mianserin und seine Verwandten, insbesondere Mirtazapin als aktuelle Neuentwicklung.

Mianserin: Geschichtliche Entwicklung

Mianserin wurde neben einer Reihe chemisch verwandter Substanzen bei Organon in den Niederlanden als Antiallergikum synthetisiert. Dem Forschungsansatz lag die Hypothese zugrunde, ein Antihistaminikum mit zusätzlichen antiserotonergen Eigenschaften könnte die herkömmlichen Antiallergika an Wirksamkeit übertreffen (80). Tierexperimentelle Testungen ließen – mehr zufällig – verhaltensmodulierende Eigenschaften der Substanz erkennen, die auf eine spezielle zentralnervöse Wirksamkeit von Mianserin hinwiesen; diese konnte auch am Menschen verifiziert werden. Aufgrund computergestützter EEG-Analysen postulierten Iul und Mitarbeiter (Übersicht bei 32) einen antidepressiven Effekt für Mianserin und bestätigten ihn in ersten klinischen Prüfungen.

In Deutschland ist Mianserin seit 1975 als Antidepressivum (Tolvin®) auf

dem Arzneimittelmarkt, seit 1991 wird es auch unter dem Handelsnamen Prisma® angeboten.

Chemische Struktur von Mianserin

Mianserin gehört strukturell zu den Piperazino-Azepinen (Abb. 1a). Es ist eine tetrazyklische Verbindung und zeigt keine chemische Verwandtschaft mit den Antidepressiva trizyklischer Grundstruktur. Die Filmtabletten enthalten Mianserin-Hydrochlorid als Racemat, wobei überwiegend das S(+)-Enantiomer für die Blockade der α_2 -Autorezeptoren (vgl. unten) und für die verhaltensmodulierenden Eigenschaften in den Depressionsmodellen verantwortlich ist (64).

Pharmakologische Wirkmechanismen von Mianserin

Das pharmakodynamische Profil von Mianserin unterscheidet sich wesentlich von denjenigen anderer Antidepressiva: Der hervorstechende Akuteffekt von Mianserin ist die Blockade kortikaler präsynaptischer α_2 -Autorezeptoren, wodurch vermehrt Noradrenalin in den synaptischen Spalt freigesetzt wird (3). Die präsynaptische Wiederaufnahme von Serotonin, Noradrenalin (im therapeutischen Dosisbereich) und von Dopamin wird nicht beeinflusst. Postsynaptisch wirkt Mianserin als mäßiggradiger α_1 -Antagonist, kortikale β -Adrenozeptoren werden durch die Substanz nicht beeinflusst (76). Dagegen blockiert Mianserin zentrale postsynaptische Serotonin-(5-Hydroxytryptamin, 5-HT-)Rezeptoren, insbesondere 5-HT₂- und 5-HT₇-, geringer auch 5-HT₁-Rezeptoren. Mianserin wirkt als starker Histamin-H₁- und, auch peripher (Magenschleimhaut!), als Histamin-H₂-Blocker (63). Dagegen werden muskarinische Acetylcholinrezeptoren allenfalls minimal beeinflusst. Anders als die trizyklischen Antidepressiva und ebenso wie die spezifischen Serotonin-Rückaufnahmehemmer zeigt Mianserin einen allenfalls unspezifischen Reserpinantagonismus.




Abb. 1a Chemische Strukturformel von Mianserin (1, 2, 3, 4, 10, 14 b-Hexahydro-2-methyl-dibenzo [c, f] pyrazino-[1, 2a]-azepin)




Abb. 1c Chemische Strukturformel von Setipitil (Tecipitil) (2, 3, 4, 9-Tetrahydro-2-methyl-1H-dibenzo [c, f] cyclohepta [1, 2-c] pyridin)




Abb. 1b Chemische Strukturformel von Mirtazapin (1, 2, 3, 4, 10, 14 b-Hexahydro-2-methylpyrazino-[2, 1a] pyrido-[2, 3c] [2] benzazepin)




Abb. 1d Chemische Strukturformel von Org 4428 (cis-1, 2, 3, 4, 4a, 13b-Hexahydro-2, 10-dimethyl-dibenzo [2, 3:6, 7] oxepino [4, 5-c] pyridin-4a-ol)

Forum Neuropsychopharmacologicum

Die längerfristige Einwirkung von Mianserin führt tierexperimentell zu einer Abnahme der Wirksamkeit von Agonisten auf das β -adrenozeptor-gekoppelte Adenylatzyklasesystem in kortikalen Neuronen (50). Welche Bedeutung dieser Effekt für die klinische Wirksamkeit von Mianserin hat, ist noch unklar. Ähnliches gilt für den Einfluß von Mianserin auf die Aktivierung des Locus coeruleus (Sitz der Noradrenalin-produzierenden Neuronen im Gehirn) durch das Corticotropin releasing hormone (CRH) (17). Eine Abnahme der Dichte postsynaptischer β -Rezeptoren (β -Downregulation) wurde ebenfalls mit der antidepressiven Wirkung der Antidepressiva in Zusammenhang gesehen, doch ist diese Hypothese mittlerweile in Frage gestellt, da unter längerer Mianserin- (auch unter Viloxazin-)Gabe eine β -Downregulation nicht beobachtet werden konnte (5).

Antidepressive Wirksamkeit von Mianserin

Unter den »Antidepressiva der zweiten Generation« gehört Mianserin zu denjenigen Substanzen, deren stimmungsaufhellender Effekt besonders gut belegt ist (56). Gegen Placebo wurde Mianserin in mindestens acht Effizienzstudien mit zusammen etwa 600 Patienten doppelblind getestet. In fünf dieser Studien fand sich eine signifikante Überlegenheit des Pharmakons. Kontrollierte Untersuchungen gegen trizyklische Referenzpräparate (Amisriptylin/Nortriptylin, Imipramin, Clomipramin, weitere verschiedene Trizyklika) führten zu jeweils gleichwertigen Therapieergebnissen und ließen bezüglich Verträglichkeit und unerwünschter Wirkungen zumeist Vorteile für Mianserin erkennen (56). Gegenüber anderen Antidepressiva der »zweiten Generation« erwies sich Mianserin in Doppelblindprüfungen ebenfalls als jeweils wirkäquivalent bei zumeist gleich guter, teilweise auch besserer Verträglichkeit. Die Vergleichssubstanzen waren Maprotilin, Trazodon (56) und die spezifischen Serotonin-Wiederaufnahmehemmer Fluoxetin, Fluvoxamin, Paroxetin und Citalopram (19). Im Vergleich zu dem reversibel binden-

den MAO-A-Hemmer Moclobemid schnitt Mianserin in zwei Doppelblindstudien an älteren Populationen günstig ab, in einer der Studien waren unter Mianserin weniger unerwünschte Wirkungen zu verzeichnen (21, 78). Zwei kontrollierte Vergleiche gegen Diazepam ließen ein gutes anxiolytisches Potential bei depressiv-ängstlichen Patienten erkennen, in der antidepressiven Wirksamkeit war Mianserin dem Benzodiazepin erwartungsgemäß überlegen. Einer Kombination aus Amisriptylin und Chlordiazepoxid erwies sich Mianserin bezüglich der antidepressiven und der anxiolytischen Effizienz als gleichwertig (71).

Im Rahmen kontrollierter Studien wurde Mianserin an ambulanten und stationären Patienten, an Patienten mit schweren Depressionen und an geriatrischen Patienten geprüft. Diagnostisch handelte es sich ganz überwiegend um »major depressive disorders« nach DSM III bzw. DSM-III-R (etwa der endogenen Depression entsprechend), teilweise aber auch um reaktiv bzw. neurotisch depressive Störungen. Eine der wenigen medikamentösen Therapiestudien bei depressiven Kindern und Adoleszenten wurde mit Mianserin in Form einer offenen Pilotstudie durchgeführt (23). Hier ließ sich ebenfalls eine gute Wirksamkeit nachweisen; die mittleren-Erhaltungsdosen lagen bei ca. 1 mg/kg Körpergewicht.

Die antidepressive Wirksamkeit von Mianserin steht mittlerweile außer Frage, sie ist derjenigen trizyklischer und neuerer Medikamente zur Behandlung depressiver Störungen gleichwertig (56).

Zur Dosierung von Mianserin

Als Erhaltungsdosis in der Standardbehandlung von Depressionen gilt der Bereich zwischen 60 und 90 mg Mianserin täglich. Dieser Dosisbereich wurde auch in der Mehrzahl der kontrollierten Wirksamkeits- und Vergleichsstudien nicht oder nicht wesentlich überschritten. Neuere Untersuchungen lassen jedoch erkennen, daß höhere Tagesdosen geeignet sind, den Therapieerfolg weiter zu verbessern. In Tabelle 1 sind eine Reihe zumeist kontrollierter Studien aufgelistet, in denen bedarfsweise

Tagesdosen bis 150 mg und mehr gegeben wurden. Die in den Arbeiten dargestellten Therapieverläufe zeigen kontinuierliche Besserungen, wobei die Verträglichkeit des Medikamentes durch Höherdosierung nicht beeinträchtigt wird; insbesondere traten keine Blutbildveränderungen auf (vgl. unten). In einigen Studien (z. B. 8) wird über einen früheren Wirkbeginn von Mianserin gegenüber der Vergleichssubstanz berichtet.

Befunde zur Eliminationsgeschwindigkeit von Mianserin beim älteren Menschen sind widersprüchlich, aktuelle Untersuchungen fanden jedoch gegenüber jüngeren Altersgruppen keine Besonderheiten (4, 42, 43). Auch beim älteren Patienten kann eine Steigerung der Tagesdosis über 90 mg hinaus den Therapieeffekt günstig beeinflussen (43).

Eine Erhaltungsdosis von Mianserin zwischen 30 und 90 mg pro die ist nach wie vor in den meisten Fällen – zumindest in der ambulanten Verordnung – ausreichend. Sollte sich hierunter allerdings binnen 14 Tagen kein befriedigendes Therapieergebnis einstellen, so erscheint aufgrund der vorliegenden Daten eine schrittweise Steigerung der Tagesdosis, im Bedarfsfalle auf bis zu 180 mg täglich, empfehlenswert. Diesem Umstand trägt die kürzlich erfolgte Einführung einer 60-mg-Tablette für Mianserin (Tolvin®) Rechnung.

Zur Frage der Blutbildveränderungen unter Mianserin

Erste Einzelfälle von Leukozytopenien bzw. Agranulozytosen unter Mianserin wurden Ende der siebziger Jahre aus Großbritannien, später auch aus dem australisch-neuseeländischen Raum berichtet (1, 2, 12, 13, 16, 27, 47, 57, 60). In Neuseeland ergab die Auswertung im Rahmen des Intensive Medicines Monitoring Programme für den Zeitraum von 1983 bis 1988 eine Inzidenz von Agranulozytosen von 1:1822 mianserinbehandelter Patienten (14, 15). In den Fällen, in denen Mianserin als einziges Medikament eingenommen worden war, lag die Inzidenz bei 1:3461 (15). Insgesamt wurden drei Todesfälle erfaßt.

Die Häufung dieser Komplikation scheint allerdings regional begrenzt

Demling: Mianserin und seine Verwandten

Tab. 1 Antidepressive Therapiestudien mit Mianserin, in denen höhere Tagesdosen (>90 mg) erreicht wurden

Autor(en) und Jahr	Studiendesign	vermeint unerwünschte Arzneimittelwirkungen (UAW) durch Dosiserhöhung > 90 mg?
McGrath et al. 1983	vs. Placebo (PL) ambulant MIA bis 150 mg	nicht ausdrücklich gesagt, aber auch hohe Dosen gut verträglich
Carmen et al. 1991	doppelblind vs. Amitriptylin (AMI) und PL ambulant MIA bis 150 mg nach Bedarf	nein
Wilcox et al. 1994	doppelblind vs. AMI und PL ambulant MIA bis 150 mg nach Bedarf	keine Hinweise
Jaukari et al. 1977	vs. AMI stationär MIA bis 120 mg	keine Aussage: „60-90 mg MIA verursachen keine ernsthaften hämatologischen, Leberfunktions- und EKG-Störungen“
Feghner et al. 1983	vs. AMI ambulant MIA bis 150 mg (x=105 mg)	keine Aussage, aber insgesamt besser verträglich als AMI
Guy et al. 1983	doppelblind vs. AMI stationär MIA bis 150 mg (x max. 127 mg)	nicht ausdrücklich gesagt, aber weniger Studienabbrüche als unter AMI
Dunkley et al. 1985	vs. Clomipramin ambulant MIA bis 150 mg (teilweise)	keine Zunahme von UAW im Studienverlauf
Perez und Ashford 1990	vs. Fluvoxamin ambulant MIA bis 180 mg (teilweise)	nein, initiale Müdigkeit verteilte sich, Studienabbrüche überwiegend initial
de Witte et al. 1985	vs. Citalopram stationär MIA bis 120 mg (10 Pat.)	nein, abnehmende Zahl von Symptomen und UAW im Studienverlauf (Dosissteigerung)
Hodel und Trum 1977	offene Feldstudie ambulant und stationär MIA vereinzelt auf 120 oder 160 mg	nein, vielmehr Verringerung der UAW unter fortlaufender Therapie
Hopman 1986	offene Studie ambulant MIA nach Bedarf bis 120 mg	nein

zu sein: eine umfangreiche britische Vergleichsstudie ergab eine Wahrscheinlichkeit für eine Leukopenie unter Mianserin wie für Amitriptylin zwischen 1:10000 und 1:100000 (34); auch Erhebungen in den alten Bundesländern, u. a. basierend auf Zahlen der Deutschen Arzneimittelkommission, ließen keine statistisch zu sichernde höhere Inzidenz gravierender Blutbildveränderungen unter Mianserin gegenüber anderen Antidepressiva erkennen (52). Aufgrund der neuseeländischen Befunde werden in der Bundesrepublik dennoch wöchentliche Kontrollen des weißen Blutbildes während der ersten Behandlungsmonate empfohlen. In dieser Zeit sollte auch verstärkt auf Zeichen vermindelter Immunresistenz (fiebrhafte Infekte, Grippe, Tonsillitiden u. a.) geachtet werden. Bei einer Gesamtleukozytenzahl unter 3000 pro mm³ ist Mianserin abzusetzen und ein Differentialblutbild anzufertigen.

Ältere Patienten scheinen von Blutbildveränderungen unter Antidepressiva, auch unter Mianserin, etwas häufiger

betroffen zu sein. Eine Differenz zwischen den Geschlechtern besteht nicht (14). Die Reaktion, von der selten auch andere Blutzellen betroffen sind, fällt bevorzugt in den Zeitraum zwischen vierter und sechster Behandlungswoche. Blutbildveränderungen, ebenfalls zumeist passager, können auch unter der Behandlung mit trizyklischen Antidepressiva auftreten; auch hier sind deshalb regelmäßige Kontrollen – in mehrwöchigen Abständen – angezeigt (5).

Mianserin: Sicherheit bei Überdosierung

Mianserin hat in Überdosis nur geringe toxische Eigenschaften. Es ist daher auch bei potentieller Suizidgefahr ein sehr »sicheres« Medikament (49, 67, 84), im Gegensatz zur überwiegenden Mehrzahl der trizyklischen Substanzen und den älteren MAO-Hemmern (9, 25, 55). In Überdosis verursacht Mianserin Müdigkeit, Anstieg oder Abfall des Blutdrucks.

Tachy- oder Bradykardien ohne Arrhythmien (10), bemerkenswerterweise keine epileptischen Anfälle, im Gegensatz zu Intoxikationen mit trizyklischen Antidepressiva oder Maprotilin (38). Einzelfälle von intrakardialen Blockbildungen (28, 31) und rezidivierenden ventrikulären Fibrillationen (30) wurden beschrieben.

Therapeutisch sind bei Intoxikationen mit Mianserin Magenspülung (wenn die Tablettenaufnahme nicht länger als vier Stunden zurückliegt, 49) und ggf. symptomatische Maßnahmen indiziert, ein spezifisches Antidot ist nicht bekannt.

Gibt es weitere Indikationen für Mianserin?

Neben depressiven und depressiv-ängstlichen Verstimmungszuständen sind weitere Indikationen für Mianserin denkbar, die sich aus den Angriffsorten der Substanz an verschiedenen zentralen Rezeptoren ergeben (vgl. oben und 65), teilweise allerdings erst tierexper-

mentell getestet wurden, z. B. Erbrechen, Opiatentzug oder Aggressivität. Humanstudien liegen vor zur Wirksamkeit bei primären Angststörungen (6, 58), zur Behandlung schizophrener Negativsyndrome in kombinierter Gabe mit Neuroleptika (51), zu Schlafstörungen (48, 54) und Zwangsstörungen (36, 79). Schon frühzeitig wurde die Substanz auf ihre migräneprophylaktische Wirksamkeit getestet (61). Es folgte eine Reihe kontrollierter Studien zu dieser (53) und anderen Indikationen aus dem Schmerzereich wie Therapie von Migräne und Spannungskopfschmerz (20), chronischem Spannungskopfschmerz (40), diabetischer (Poly-) Neuropathie (72), chronischem idiopathischem Schmerz als Symptom einer »larvierten« Depression (81) und chronischen Schmerzen unterschiedlicher Genese (59); die drei letztgenannten Studien erbrachten negative Ergebnisse. Manna et al. (44) fanden in einer Vergleichsstudie zu Fluvoxamin eine gute Wirksamkeit von Mianserin gegen mäßiggradige Spannungskopfschmerzen bei Depressionen. Bei relativ niedriger Tagesdosierung (30-60 mg) war Mianserin gegen Spannungskopfschmerzen nicht jedoch gegen Kreuzschmerzen Placebo signifikant überlegen (41).

Insgesamt lagen in den genannten Schmerzstudien die Tagesdosen von Mianserin zwischen 30 und 90 mg, also im unteren bis mittleren therapeutisch empfohlenen Bereich. Tanum (77) testete in einer Pilotstudie Mianserin

in Tagesdosen zwischen 90 und 120 mg erfolgreich gegen chronische idiopathische Schmerzen des Abdomens, wozu auch Fälle mit irritablem Kolon gehört haben dürften. Unter der gleichen Indikation waren die niedrigeren Dosen in der Studie von Loldrup et al. (41) weniger effizient.

Mianserin erscheint somit gut wirksam in der Migräneprophylaxe, gegen akute Migräne, gegen mäßiggradige Spannungskopfschmerzen und, in höherer Dosierung, möglicherweise auch gegen psychosomatische abdominale Schmerzen (z. B. Colon irritabile).

Eine aktuelle Neuentwicklung: Mirtazapin (Org 3770)

Eine weitere tetrazyklische Verbindung aus der Reihe der Piperazino-Azepine, für die eine antidepressive Wirksamkeit nachgewiesen wurde, ist Mirtazapin.

Diese Verbindung unterscheidet sich von Mianserin strukturell durch den kondensierten Pyridinring (statt des kondensierten Benzolringes); aus der starken Interaktion des zusätzlichen Stickstoffatoms mit dem benachbarten Stickstoffatom resultiert ein erheblicher Unterschied zwischen beiden Verbindungen in der Verteilung der Elektronendichte und damit auch in den pharmakologischen Eigenschaften (Abb. 1b).

Bei den pharmakokinetischen Eigenschaften liegt der Unterschied in der

höheren Bioverfügbarkeit von Mirtazapin (Tab. 2).

Pharmakodynamisch ist Mirtazapin wie Mianserin ein α_2 -Antagonist, bewirkt also ebenfalls über den präsynaptischen α_2 -Autorezeptor eine Anreicherung von Noradrenalin im synaptischen Spalt (Blockade des negativen Feedback in die präsynaptische Zelle) (Abb. 2). Ebenfalls über eine α_2 -Blockade kommt es zu einer verstärkten Aktivität serotonerger Neuronen, vermittelt durch α_1 -Rezeptoren auf diesen Zellkörpern; im Gegensatz zu Mianserin besitzt Mirtazapin nur eine sehr schwache α_1 -adrenolytische Potenz, so daß hier das freigesetzte Noradrenalin mit diesen Rezeptoren nahezu uneingeschränkt interagieren kann. Schließlich wird über eine Blockade auch der α_2 -Heterorezeptoren an den serotonergen präsynaptischen Membranen durch Mirtazapin (nicht aber durch Mianserin) die terminale Freisetzung des Serotonins gefördert. Das freigesetzte Serotonin (5-Hydroxytryptamin = 5-HT) wirkt nun agonistisch auf postsynaptische 5-HT₁-Rezeptoren, was mit der antidepressiven Wirksamkeit in Zusammenhang gesehen wird, wohingegen die postsynaptischen 5-HT₂- und 5-HT₂-Rezeptoren durch Mirtazapin blockiert werden; die 5-HT₂-Blockade wird mit der schlafverbessernden und anxiolytischen, die 5-HT₂-Blockade ebenfalls mit der anxiolytischen Wirkung in Verbindung gebracht (18). Des Weiteren verhindert die Blockade der 5-HT₂- und der

Tab. 2. Pharmakokinetische Daten von Mianserin und Mirtazapin

Pharmakokinetische Parameter	Mianserin	Mirtazapin
Bioverfügbarkeit:	ca. 20-30 %	50 %
Plasmabindung:	96 %	85 %
Steady state im Plasma erreicht nach:	6 Tagen	2-5 Tagen
Induktion metabolisierender Leberenzyme:	nein	nein
Hauptmetabolisierungsweg:	Demethylierung, 8-Hydroxylierung	Demethylierung, 8-Hydroxylierung
aktive Metaboliten:	ja (Desmethylnianserin, 8-Hydroxymianserin)	Desmethylnirtazapin mit ca. 30 % Aktivität und wesentlich geringerer Plasmakonzentration
Plasma-Eliminations-Halbwertszeit:	ca. 30 Stunden	20-40 Stunden
Hauptausscheidungsorgan:	Niere (70 %)	Niere (85 %)

Demling: Mianserin und seine Verwandten




Abb. 2 Schematische Darstellung des pharmakologischen Wirkmechanismus von Mirtazapin, in der Abbildung mit dem Handelsnamen für die BRD (Remergil®) bezeichnet NA= Noradrenalin, 5-HT= 5-Hydroxytryptamin = Serotonin

5-HT₂-Rezeptoren unerwünschte Begleiteffekte aufgrund unspezifischer Serotoninstimulation, wie sie etwa unter selektiven Serotonin-Wiederaufnahmehemmern (Nausea, Unruhezustände), MAO-Hemmern (Unruhe) und Venlafaxin (Nausea) beobachtet werden.

Der wesentliche Wirkunterschied zwischen den beiden tetrazyklischen Substanzen besteht also darin, daß Mirtazapin zusätzlich zu der noradrenergen Wirkung (wie Mianserin) eine ausgeprägte serotonerge Wirkung aufweist, die sich spezifisch über den 5-HT₁-Rezeptor entfaltet. Die Wirkgruppe, der Mirtazapin – neben cvtl. anderen Substanzen – angehört, wird deshalb als »Noradrenalin and Specific Serotonin Antidepressant« – NaSSA – bezeichnet (wohl in Anlehnung an den Terminus der »Selective Serotonin Reuptake Inhibitors«: SSRI).

Mirtazapin wurde in kontrollierten Studien auf seine klinische Wirksam-

keit gegen depressive Störungen geprüft. Die Tagesdosen in diesen Studien, die (8/95) erst zum Teil publiziert sind, lagen zwischen 15 und 60 mg. Gegenüber Placebo zeigte sich eine signifikante Überlegenheit (11, 83). Die stimmungsaufhellende Wirkung war derjenigen von Standardantidepressiva wie Amitriptylin (7, 75, 86), Clomipramin (68) und Doxepin (45) ebenbürtig, derjenigen von Trazodon überlegen (82). Die Untersuchungskollektive umfaßten unter anderem Patienten mit schweren Depressionen (Hamilton-Summenscore über 25) und stationäre Patienten (82, 86).

Auch auf Angstsymptome und Schlafstörungen im Rahmen depressiver Erkrankungen hat Mirtazapin einen günstigen Einfluß, wie aus Metaanalysen der placebo- und amitriptylinkontrollierten Studien hervorgeht (74). Der positive Einfluß auf klinisch relevante Schlafparameter war bereits in tierexperimentellen Studien und an gesunden

Probanden (69) gezeigt worden. Primäre Angststörungen sind einer Therapie mit Mirtazapin gut zugänglich (73), doch bedarf diese Indikation – auch wegen ihrer klinisch-praktischen Bedeutung – der Bestätigung durch weitere Studien auf der Basis von ICD-10- oder DSM-Kriterien.

Beim Vergleich der Verträglichkeit von Mirtazapin mit Amitriptylin ergab sich kein Überwiegen unerwünschter Effekte, insbesondere fehlten anticholinerge Begleitwirkungen bei Mirtazapin nahezu vollständig. Im Placebovergleich traten Sedierung, Appetitsteigerung, Mundtrockenheit und Gewichtszunahme unter Verum häufiger auf, unter Placebo überwogen Kopfschmerzen und Gewichtsreduktion (74).

Weitere Neuentwicklungen

Seit 1989 ist eine weitere tetrazyklische Verbindung in Japan zugelassen,

Forum Neuropsychopharmacologicum

Setipilin oder Tedipilin (Org 8282 oder MO 8282, japanischer Handelsname Tecipul, Abb.1c), das Eigenschaften von Mianserin (potenter Serotonin-, Histamin-H₁- und präsynaptischer α_2 -Antagonismus) mit einer Noradrenalin-Wiederaufnahmeinhibition vereinigt. Die Eliminations-Halbwertszeit beträgt ca. 11 Stunden, gebräuchliche Tagesdosen bewegen sich zwischen 6 und 9 mg. Es liegen Wirksamkeitsnachweise zu den Indikationen »Depressionen« (37) und »Negativsymptome der Schizophrenie« (39) vor.

Eine ebenfalls tetrazyklische Substanz in Analogie zur Strukturklasse der Piperazin-Azepine ist derzeit als Antidepressivum in Phase III der klinischen Erprobung (Org 4428, Abb.1d). Es handelt sich, gewissermaßen als Gegenstück zu den SSRI, um einen selektiven Noradrenalin-Wiederaufnahmehemmer (70). Im Sinne der eingangs erwähnten »Verfeinerung« sind daher kaum Interaktionen mit anderen Rezeptoren zu erwarten. Insbesondere zeigt Org 4428 im Gegensatz zu trizyklischen Noradrenalin-Wiederaufnahmehemmern wie Desipramin oder Maprotilin keine anticholinergen Effekte, auch fehlt eine sedierende Begleitwirkung.

Weitere Verbindungen, die Strukturvarianten von Mianserin darstellen, sind als Migränemittel und -prophylaktika bzw. als Antidepressiva mit guten anxiolytischen Eigenschaften in der Erprobung.

Schlußbemerkung

Mianserin hat sich mittlerweile über 20 Jahre lang in der Therapie depressiver Störungen bewährt, und es schien verwunderlich, daß der großen Zahl eingeführter trizyklischer Antidepressiva bislang nur ein »echtes« Tetrazyklikum gegenüberstand. Nunmehr formiert sich, ausgehend von Mianserin, ein neues Arsenal zur Therapie depressiver Störungen. Während die Trizyklika hinsichtlich ihrer therapeutischen und Verträglichkeitseigenschaften eine relativ homogene Gruppe bilden, bringen strukturelle Variationen des Tetrazyklicums Mianserin eine Reihe neuer Eigenschaften hervor, die thera-

pielevant sind und gleichzeitig einen Fortschritt im Sinne besserer Verträglichkeit bedeuten. Den theoretischen Hintergrund für den postulierten klinischen Wirkmechanismus bilden weiterhin die Aminmangelhypothesen, die allerdings hier in weitgehend »reiner«, im Falle des Mirtazapins sogar in kombinierter (Noradrenalin und Serotonin) Form verwirklicht sind. Das therapeutische Potential, das der tetrazyklischen Grundstruktur des Mianserin innewohnt, ist offenkundig noch nicht ausgeschöpft. Es eröffnen sich hier neue, zweifellos vielversprechende Möglichkeiten für die Pharmakotherapie in der Psychiatrie und vielleicht auch für weitere Gebiete der medikamentösen Behandlung.

LITERATUR

1. Adams PC, Robinson A, Reid MM et al. Blood dyscrasias and mianserin. *Postgrad Med J* 1983; 59: 31-3.
2. Adverse Drug Reactions Advisory Committee. Mianserin. A possible cause of neutropenia and agranulocytosis. *Med J Aust* 1988; 2: 673-4.
3. Baumann PA, Maitre L. Blockade of presynaptic α -receptors and of amine uptake in the rat brain by the antidepressant mianserin. *Naunyn-Schmiedeberg's Arch Pharmacol* 1977; 300: 31-7.
4. Bege EJ, Shannan JR, Kidd JE et al. Variability in the elimination of mianserin in the elderly. *Br J Clin Pharmacol* 1988; 77: 445-51.
5. Benkert O, Hippert H. Psychiatrische Pharmakotherapie. 5. Aufl. Berlin, Heidelberg, New York: Springer 1992.
6. Bjurtnaes A, Block JM, Hafstad PE et al. A multicentre placebo-controlled trial comparing the efficacy of mianserin and chlordiazepoxide in general practice patients with primary anxiety. *Acta Psych Scand* 1982; 66: 199-207.
7. Bremner JD. A double-blind comparison of Org 3770, amitriptyline and placebo in major depression, im Druck.
8. Carman JS, Aldrich H, Wyatt-Knowles E et al. A controlled study of mianserin in moderately to severely depressed outpatients. *Psychopharmacol Bull* 1991; 27: 135-8.
9. Cassidy S, Henry J. Fatal toxicity of antidepressant drugs in overdose. *Br Med J* 1987; 295: 1021-4.
10. Chand S, Crome P, Dawling S. One hundred cases of acute intoxication with mianserin hydrochloride. *Pharmacopsychiatry* 1981; 14: 15-7.
11. Claghorn JL, Lessem MD. A double-blind placebo controlled study of Org 3770 in depressed outpatients. *J Affect Disord* 1993; 34: 165-71.
12. Clink HM, Shaw WL. Mianserin-induced agranulocytosis. *Br Med J* 1982; 285: 437-8.

Risperdal 1 mg/- 2 mg/- 3 mg/- 4 mg Verschreibungspflichtig.
Wirkstoff: Risperidon. Zusammensetzung: 1 Filmtablette enthält 1 mg, 2 mg, 3 mg, 4 mg Risperidon. Sonstige Bestandteile: Lactose, Maisstärke, Magnesiumstearat, Natriumdoodecylsulfat, Propylenglykol, Methylhydroxypropylcellulose, mikrokristalline Cellulose, hochdisperses Siliciumdioxid; zusätzlich Risperdal 2 mg: Talkum, Farbstoffe (E 110, E 171); zusätzlich Risperdal 3 mg: Talkum, Farbstoffe (E 104, E 171); zusätzlich Risperdal 4 mg: Talkum, Farbstoffe (E 104, E 132, E 171). Anwendungsgebiete: Chronische schizophrene Psychosen einschließlich Exazerbationen. Gegenanzeigen: Überempfindlichkeit gegenüber Wirkstoff od. weiteren Bestandteilen des Arzneimittels; bestehende, nicht durch Medikamente bedingte Hyperprolaktinämie; Kinder und Jugendliche. Nur mit bes. Vorsicht anwenden bei Leber- und Niereninsuffizienz; vorbestehende Parkinson'scher Erkrankung, da theoretisch Verschlechterung möglich; anamnestisch bek. Epilepsie; gleichzeitiges Vorliegen von Prolaktin-abhängigen Tumoren, z.B. Prolaktinomen der Hypophyse; möglicherweise Prolaktin-abhängigen Tumoren, z.B. epihänelen Mamma-Tumoren; Patienten mit schweren Herz-Kreislauf-Erkrankungen; patholog. Veränderungen d. Blutbildes; älteren Patienten. Sehr sorgfältige Abwägung der Vorteile gegenüber den Risiken einer Behandlung während der Schwangerschaft (Risperidon zeigte im Tierversuch keine teratogene Wirkung). Mit Risperdal behandelte Frauen sollten nicht stillen. Nebenwirkungen: Müdigkeit; Schläfrigkeit; Agitation, Angstzustände, Kopfschmerzen. Seltener: Somnolenz, Schwäche, Benommenheit, Konzentrationssstörungen, Obstipation, Dyspepsie, Übelkeit, Erbrechen, Bauchschmerzen, Sehstörungen, Priapismus, erektile Dysfunktion, Ejakulationsstörungen, Störungen des Orgasmus, Harninkontinenz, Rhinitis, Hautausschlag u. and. allerg. Reaktionen. Gelegentlich: (Orthostat.) Hypotension, (Reflex-)Tachykardie oder Hypertonie. Bes. Vorsicht bei bek. kardiovaskulären Erkrankungen, hier nur langsame, vorrührige Dosiseinstellung. Gelegentlich extrapyramidale Symptome (Tremor, Rigorität, Hypersalivation, Bradykinesie, Akathisie, akute Dystonie) sind i. d. Regel gering ausgeprägt und bei Dosierend. und/oder Gabe von Anticholinergika reversibel. Extrapyramidale Symptome wurden als Risikofaktor für die Entwicklung von in Einzelfällen unter Risperdal beobachteten tardiven Dyskinesien beschrieben. Falls Hinweise für tardive Dyskinesien auftreten, Absetzen aller antipsychotischen Medikamente in Erwägung ziehen. In Einzelfällen malignes neuroleptisches Syndrom mit Fieber, Muskelrigidität, autonomer Instabilität, Bewußtseinsstörung und erhöhten CPK-Werten; außerdem in sehr seltenen Einzelfällen Hypothermie. Schon bei Frühwarnzeichen des malignen neuroleptischen Syndroms intensives med. Maßnahmen, sofortiges Absetzen aller Neuroleptika. Differenzialdiagnose zur Kataris von einschneidender Bedeutung. Gewichtszunahme, Ödem, Bildung, und/oder Gabe von Antipsychotika. Erhöhung der Leberwerte möglich, phos. erhöhte Prolaktinspiegel mit Galaktorrhoe, Gynäkomastie, Amenorrhoe od. Menstruationsstörungen. Zwar wurde bisher kein Zusammenhang zwischen Neuroleptikather. und Brustkrebs deutl., doch Vorsicht bei entsprechender Anamnese. Einzelfallberichte von Störungen des Wasserhaushaltes durch übermäßige Flüssigkeitsaufnahme od. das Syndrom der inappropriaten Sekretion von antidiuretischem Hormon (SIADH). Einzelfälle von Regulationsstör. d. Körpertemperatur u. Krampfanfall. Vereinz. Verdachtsfälle: Photosensibilisier., Muskelschwäche, Panikreaktion, mäßige Leukopenie u.a. Leichter Abfall der Thrombozyten. Verzehrswarnhinweis: Veränderung des Reaktionsvermögens mögl., so daß Fähigkeit z. Fahren, am Straßenverkehr od. Bedienen von Maschinen beeinträchtigt wird (bes. mit Alkohol). Handelsformen und Preise: AVP incl. USt. (Stand 05/95) Risperdal 1 mg OP: 20 Filmtabl. (N1) DM 50,80; KP Risperdal 2 mg OP: 20 Filmtabl. (N1) DM 94,45; 50 Filmtabl. (N2) DM 217,71; KP Risperdal 3 mg OP: 20 Filmtabl. (N1) DM 135,15; 50 Filmtabl. (N2) DM 322,41; KP Risperdal 4 mg OP: 20 Filmtabl. (N1) DM 174,20; 50 Filmtabl. (N2) DM 424,48; KP. Art und Dauer der Anwendung: Einnahme mit oder ohne Nahrung, Anwendungsdauer bestimmt behandelnder Arzt. Wechselwirkungen mit anderen Mitteln: Risiken bei gleichzeitiger Einnahme mit anderen Med. nicht systemat. untersucht, z.B. Lithium und Arzneimittel mit Ansatz am serotonergen System. Wechselwirkungen theoretl. mit allen zentral wirkenden Substanzen mögl. Vorsicht bei Begleitmedikation. Komb. mit Dopamin-Agonisten (z.B. Levodopa) kann deren Wirkung vermindern. In Komb. mit Carbamazepin kann Dosiserhöhung notw. sein, ebenso bei Komb. m. anderen Enzyminduktoren, nach Absetzen sollte Risperdal-Dosis angepasst (gesenkt) werden. Additive Wirkung mit Antihypertensiva mögl. Lagerungshinweis: Vor Licht und Feuchtigkeit schützen!

JANSSEN

Organon

61407 Neuen

65782 Oberschlittenham

Demling: Mianserin und seine Verwandten

13. Clink HM. Mianserin and blood dyscrasias. *Br J Clin Pharmacol* 1983; 15: 291S-293S.
14. Coulter DM, Edwards IR. Mianserin and agranulocytosis in New Zealand. *Lancet* 1990; 336: 785-7.
15. Coulter DM. Mianserin and agranulocytosis. *Lancet* 1990; 11: 1010.
16. Curson DA, Hale AS. Mianserin and agranulocytosis. *Br Med J* 1979; 1: 378-9.
17. Curtis AL, Valentino RJ. Acute and chronic effects of the atypical antidepressant, mianserin, on brain noradrenergic neurons. *Psychopharmacology* 1991; 103: 330-8.
18. de Boer T, Ruigt GSJ. The selective α_2 -adrenoceptor antagonist mirtazapine (Org 3770) enhances noradrenergic and serotonin $_1A$ -mediated serotonergic neurotransmission. *CNS Drugs* 1995; 4 (suppl 1): 29-38.
19. Demling J et al. Klinik der nicht-trizyklischen Antidepressiva. In: *Neuro-Psychopharmaka. Ein Therapie-Handbuch*. Band 3: Antidepressiva und Phasenprophylaktika. Riederer P, Lutz G, Pöhlinger W (Hrsg). Wien, New York: Springer 1993: 127-251.
20. Denaro A, Martucci N, Ruggieri S et al. Headache and noradrenergic involvement: the effects of α_2 -stimulants and α_2 -antagonists. *Acta Psychiatr Scand* 1985; 72 (Suppl. 320): 21-5.
21. de Vanna M, Kummer J, Agnoli A et al. Moclobemide compared with second-generation antidepressants in elderly people. *Acta Psychiatr Scand* 1990; 82 (Suppl. 320): 64-6.
22. de Wilde J, Merrens C, Fredriksen Overø K, Høpfer Petersen HE. Clitalopram versus mianserin. A controlled, double-blind trial in depressed patients. *Acta Psychiatr Scand* 1985; 72: 89-96.
23. Dugas M, Mounen MC, Hallon O, Miran P. Treatment of childhood and adolescent depression with mianserin. *Acta Psychiatr Scand* 1985; 72 (Suppl. 321): 48-53.
24. Dunbar GC, Naarala M, Hiltunen H. A double-blind group comparison of mianserin and clomipramine in the treatment of mildly depressed psychiatric outpatients. *Acta Psychiatr Scand* 1985; 72 (suppl 230): 60-6.
25. Farmer RDT, Pinder RM. Why do fatal overdose rates vary between antidepressants? *Acta Psychiatr Scand* 1989; 80 (Suppl. 354): 25-35.
26. Feighner JP, Jacobs RS, Jackson RE et al. A double-blind comparative trial with mianserin and amitriptyline in outpatients with major depressive disorders. *Br J Clin Pharmacol* 1983; 15: 227S-237S.
27. Forgan-Smith J, Leslie P. Neutropenia and mianserin. *Med J Australia* 1985; 143: 398.
28. Green SDR, Kendall-Taylor P. Heart block in mianserin hydrochloride overdose. *Br Med J* 1977; 2: 1190.
29. Guy W, McEvoy JM, Hsu TA et al. A double-blind clinical trial of mianserin versus amitriptyline: differentiation by adverse symptomatology. *Pharmacotherapy* 1983; 3: 45-51.
30. Hackeli WE, Schwenenherger RA, Scholer A. Recurrent ventricular fibrillation in mianserin intoxication. *Br Med J* 1991; 302: 415-6.
31. Hla KK, Boyd O. Mianserin and complete heart block. *Human Toxicol* 1987; 6: 401-2.
32. Hodel J, Trum JM. Ergebnisse einer Feldstudie an ambulanten und stationären Patienten mit einem neuen Antidepressivum. *Schweiz Rundschau Med (PRAXIS)* 1977; 66: 1085-92.
33. Hopman H. Mianserin in outpatients with depressive illness, in dosage up to 130 mg daily. *Curr Med Res Opin* 1980; 6 (Suppl. 7): 107-14.
34. Inman WHW. Blood disorders and suicide in patients taking mianserin or amitriptyline. *Lancet* 1980; 11: 90-2.
35. Jaskari MO, Ahlfors UG, Ginman L et al. Three double-blind comparative trials of mianserin (ORG GB 94) and amitriptyline in the treatment of depressive illness. *Pharmacopsychiatry* 1977; 10: 101-3.
36. Jaskari MO. Observations on mianserin in the treatment of obsessive neurones. *Curr Med Res Opin* 1980; 6 (Suppl. 7): 128-31.
37. Kamimura M, Aoba A, Yamaguchi N et al. The effect of age on plasma level of setipiline maleate in depressed patients. *Prog Neuropsychopharmacol Biol Psychiatry* 1994; 18: 1015-26.
38. Knudsen K, Heath A. Effects of self-poisoning with maprotiline. *Br Med J* 1984; 288: 601-3.
39. Kuniyoshi M, Nakamura J, Mura C, Inanaga K. Effectiveness of concomitant setipiline maleate (Tecipal) on negative symptoms of schizophrenia. *Prog Neuropsychopharmacol Biol Psychiatry* 1994; 18: 339-46.
40. Langemark M, Lørdrup D, Boch P, Olesen J. Clomipramine and mianserin in the treatment of chronic tension headache. A double-blind, controlled study. *Headache* 1990; 30: 118-21.
41. Lørdrup D, Langemark M, Hansen HJ et al. Clomipramine- and mianserin in chronic idiopathic pain syndrome. *Psychopharmacology* 1989; 99: 1-7.
42. Leinonen E. Serum mianserin concentrations in psychiatric inpatients of different ages. *Acta Psychiatr Scand* 1991; 81: 278-82.
43. Leinonen E, Koponen H, Lepola U. Serum mianserin and ageing. *Prog Neuro-Psychopharmacol & Biol Psychiatr* 1994; 18: 833-45.
44. Manna V, Bolino F, Di Cenzo L. Chronic tension-type headache, mood depression and serotonin: therapeutic effects of fluvoxamine and mianserin. *Headache* 1994; 34: 44-9.
45. Marttila M, Jääskeläinen J, Järvi R et al. A double-blind study comparing the efficacy and tolerability of Org 3770 and doxepin in patients with major depression. *Im Druck*.
46. McGrath PJ, Rahkin JG, Stewart JW et al. Placebo-controlled study of mianserin in depressed outpatients. *Neuropsychobiology* 1985; 14: 128-32.
47. McHarg AM, McHarg JF. Leucopenia in association with mianserin treatment. *Br Med J* 1979; 1: 623.
48. Mendlewicz J, Dunbar GC, Hoffman C. Changes in sleep EEG architecture during the treatment of depressed patients with mianserin. *Acta Psychiatr Scand* 1985; 72 (Suppl. 320): 26-9.
49. Meredith TJ, Vale JA. Poisoning due to psychotropic agents. *Adverse Drug React Acute Poisoning Rev* 1985; 412: 83-126.
50. Mishra R, Janovsky A, Suber F. Action of mianserin and zimefidine on the noradrenaline receptor coupled adenylyl cyclase system in brain: subsensitivity without reduction in β -adrenergic receptor binding. *Neuropharmacology* 1982; 19: 983-7.
51. Mizuki Y, Kajimura N, Kai S et al. Effects of mianserin in chronic schizophrenia. *Prog Neuro-Psychopharmacol & Biol Psychiatry* 1992; 16: 517-28.
52. Müller HJ, Meier K, Wernicke T. Empirical investigation on the risk of agranulocytosis/leucopenia under medication with antidepressants. *Pharmacopsychiatry* 1988; 21: 304-5.
53. Mowro P, Swade C, Coppen A. Mianserin in the prophylaxis of migraine: a double-blind study. *Acta Psychiatr Scand* 1985; 72 (suppl 320): 98-103.
54. Montgomery SA. The effect of mianserin on sleep and cardiac function. *Curr Med Res Opin* 1980; 6: 23-8.
55. Montgomery SA, Baldwin D, Green M. Why do amitriptyline and dothiepin appear to be so dangerous in overdose? *Acta Psychiatr Scand* 1989; 80 (Suppl. 354): 47-53.
56. Montgomery SA, Bullock T, Pinder RM. The clinical profile of mianserin. *Nord Psykiatr Tidsskr* 1991; 45 (Suppl. 24): 27-35.
57. Morgan CA, Donaldson MD. Mianserin and agranulocytosis. *Med J Australia* 1986; 144: 165.
58. Murphy JE. Mianserin in the treatment of depressive illness and anxiety states in general practice. *Br J Clin Pharmacol* 1978; 5: 815-825.
59. Onghena P, De Cuyper H, Van Houdenhove B, Verstraeten D. Mianserin and chronic pain: a double-blind placebo-controlled process and outcome study. *Acta Psychiatr Scand* 1993; 89: 198-204.
60. Page CE. Mianserin-induced agranulocytosis. *Br Med J* 1982; 284: 1912-3.
61. Peet M, Behagel H. Mianserin: a decade of scientific development. *Br J Clin Pharmacol* 1978; 5: 5S-9S.
62. Perez A, Ashford JJ. A double-blind, randomized comparison of fluvoxamine with mianserin in depressive illness. *Curr Med Res Opin* 1990; 12: 234-41.
63. Pinder RM, van Delft AML. Pharmacological aspects of mianserin. *Acta Psychiatr Scand* 1980; (Suppl. 302): 59-71.
64. Pinder RM. Adrenoceptor interactions of the enantiomers and metabolites of mianserin: are they responsible for the antidepressant effect? *Acta Psychiatr Scand* 1985; 72 (Suppl. 320): 1-9.
65. Pinder RM. Mianserin. Pharmacological and clinical correlates. *Nord Psykiatr Tidsskr* 1991; 45: 13-26.
66. Pinder RM, Wieringa JH. Third-generation antidepressants. *Medic Res Rev* 1993; 13: 259-325.

Forum Neuropsychopharmacologicum

67. Proudfoot AT. Acute poisoning with antidepressants and lithium. *Prescribers' Journal* 1986; 26: 97-106.
68. Richou H, Ruimy P, Charbaut J et al. A multicentre, double-blind, clomipramine-controlled efficacy and safety study of Org 3770 (in Dutch).
69. Ruigt GSF, Kemp B, Groenhout CM et al. Effect of the antidepressant Org 3770 on human sleep. *Eur J Clin Pharmacol* 1990; 38: 551-4.
70. Ruigt GSF, de Boer T, Bruckkamp C et al. Pharmacological profile of a new, highly selective noradrenaline reuptake blocker. Org 4428. *Neuropharmacology*, in Vorbereitung.
71. Saletsu B, Grünberger J. Changes in clinical symptomatology and psychometric assessments in depressed patients during mianserin and combined amitriptyline/chlordiazepoxide therapy: a double blind comparison. *Curr Med Res Opin* 1980; 6 (Suppl. 7): 52-62.
72. Sindrup SH, Tuxen C, Gram LF et al. Lack of effect of mianserin on the symptoms of diabetic neuropathy. *Eur J Clin Pharmacol* 1992; 43: 251-5.
73. Sitsen JMA, Moors J. Mirtazapine, a novel antidepressant, in the treatment of anxiety symptoms. Results from a placebo-controlled trial. *Drug Invest* 1994; 8: 339-44.
74. Sitsen JMA, Zivkov M. Mirtazapine: clinical profile. *CNS Drugs* 1995; 4 (suppl. 1): 39-48.
75. Smith WT, Glaudin V, Panagides J, Gilvary E. Mirtazapine vs. amitriptyline vs placebo in the treatment of major depressive disorder. *Psychopharmacol Bull* 1990; 26: 191-6.
76. Tang SW, Seeman P. Effect of antidepressant drugs on serotonergic and adrenergic receptors. *Nauwijn-Schmiedberg's Arch Pharmacol* 1984; 311: 255-61.
77. Tanum L. The effect of mianserin in chronic idiopathic abdominal pain. A pilot study. *Nord J Psychiatry* 1993; 47: 351-4.
78. Tiller J, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and mianserin in elderly depressed patients. *Int J Geriatr Psychiatry* 1990; 5: 199-204.
79. Väisänen E, Nunnikko-Pelkonen A, Tienari P, Kanta P. Mianserin hydrochloride (Org GB-94) in the treatment of obsessional states. *J Int Med Res* 1977; 5: 289-91.
80. van der Burg WJ, Bonta IL, Delobelk J et al. A novel type of substituted piperazine with high antiserotonin potency. *J Medicin Chem* 1970; 1: 35-9.
81. van Houdenhove B, Verstraeten D, Onghena P, De Cuyper H. Chronic idiopathic pain, mianserin and "masked" depression. *Psychother Psychosom* 1992; 58: 46-53.
82. van Muisaert M, de Wilde J, Vereecken A et al. Mirtazapine is more effective than trazodone: a double-blind controlled study in hospitalized patients with major depression. *Int Clin Psychopharmacol* 1995; 10: 3-10.
83. Vartiainen H, Leinonen E. Double-blind study of mirtazapine and placebo in hospitalized patients with major depression. *Eur Neuropsychopharmacol* 1994; 4 (2): 145-50.
84. Vuori E, Ruohonen A, Penttilä A et al. Fatal poisonings with antidepressants in Finland 1985-1987. *Acta Psychiatr Scand* 1989; 80 (Suppl. 354): 55-60.
85. Wilcox CS, Cohn JB, Katz BB et al. A double-blind, placebo-controlled study comparing mianserin and amitriptyline in moderately depressed outpatients. *Int Clin Psychopharmacol* 1994; 9: 271-9.
86. Zivkov M, De Jongh GD. Org 3770 versus amitriptyline: a 6-week randomized double-blind multicentre trial in hospitalized depressed patients. *Hum Psychopharmacol Clin Exp* 1995; 10: 173-81.

Korrespondenzadresse:

Priv.-Doz. Dr. Joachim Demling
 Psychiatrische Universitätsklinik
 Schwabachanlage 6
 D-91054 Erlangen

In: Vistosky H, Lich Mak F, Lopez-Ibor JJ, eds.
Abstracts of the 10th World Congress of Psychiatry,
Madrid, August 23-28, 1996. S.I., s.n., 1996;2:302.

Mechanism of Action of the Antidepressant Mirtazapine

Ge Ruigt, Chris Broekkamp, Henk Berendsen, Anon van Delft. Organon,
Department of Neuropsychopharmacology, P.O. Box 20, Oss, 3540 BH, The
Netherlands

Objective: We report here on our progress in explaining the properties of the
new antidepressant mirtazapine, by its spectrum of affinities for adrenergic and
serotonergic receptors.

Method: The techniques used are receptor binding, micro-dialysis and animal
behaviour.

Results: Mirtazapine is a powerful antagonist for the presynaptically located
 α_2 receptors and for 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C} and 5-HT₃ receptors. Similar to
noradrenergic terminals the serotonergic terminals undergo inhibitory control
by α_2 receptor activation. Blockade of these receptors by mirtazapine leads to
enhancement of both noradrenergic and serotonergic transmission. This indirect
serotonin enhancement leads to indirect activation of those serotonin receptors
which are not blocked by mirtazapine, such as 5-HT_{1A} receptors. In rats, we
studied overt unconditioned symptoms evoked by selective serotonin agonists
and by serotonin reuptake inhibitors (SSRIs). Both mirtazapine as well as SSRIs
indirectly activate 5-HT_{1A} receptors, whereas 5-HT_{2A}, 5-HT_{2B}, 5-HT_{2C} and 5-HT₃
receptors are blocked by mirtazapine but indirectly activated by SSRIs.

Conclusion: These results suggest that 5-HT_{1A} receptor activation contributes
to the antidepressant effect of mirtazapine. Blockade of 5-HT_{2B} and 5-HT₃
receptors can explain the low incidence of typical SSRI related side effects,
such as nausea and headache, seen during the clinical use of mirtazapine.
Furthermore, blockade rather than activation of 5-HT_{2C} receptors explains that
mirtazapine neither has negative impact on sexual functions nor induces appetite
inhibition.

References

- [1] De Boer Th, Ruigt GSF and Berendsen HMG: The α_2 -selective adrenoceptor antagonist
Org 3770 (mirtazapine, Remeron®) enhances noradrenergic and serotonergic trans-
mission. *Munich Psychopharmacology* 10: S107-118, 1995.
- [2] De Boer Th, Ruigt GSF: The selective α_2 -adrenoceptor antagonist mirtazapine (Org
3770) enhances noradrenergic and 5-HT_{1A}-mediated serotonergic neurotransmission.
CNS Drugs 4 (Suppl 4): 28-38, 1995.